

Article

Biakamides A–D, unique polyketides from a marine sponge, act as selective growth inhibitors of tumor cells adapted to nutrient starvation

Naoyuki Kotoku, Ryosuke Ishida, Hirokazu Matsumoto, Masayoshi Arai,
Kazunari Toda, Andi Setiawan, Osamu Muraoka, and Motomasa Kobayashi

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.joc.6b02948 • Publication Date (Web): 16 Jan 2017

Downloaded from <http://pubs.acs.org> on January 19, 2017

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.



ACS Publications

Biakamides A–D, unique polyketides from a marine sponge, act as selective growth inhibitors of tumor cells adapted to nutrient starvation

Naoyuki Kotoku ^{a,*†}, Ryosuke Ishida ^{a,†}, Hirokazu Matsumoto ^a, Masayoshi Arai ^a,
Kazunari Toda ^a, Andi Setiawan ^b, Osamu Muraoka ^c, and Motomasa Kobayashi ^{a,*}

^a Graduate School of Pharmaceutical Sciences, Osaka University, Yamada-oka 1-6,
Suita, Osaka 565-0871, Japan


^b Department of Chemistry, Faculty of Science, Lampung University, Jl. Prof. Dr.
Sumantri Brodjonegoro No. 1, Bandar Lampung 35145, Indonesia

^c School of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashi-osaka, Osaka
577-8502, Japan

[†] These authors contributed equally to this work.

* Corresponding authors. Tel: +81-6-6879-8215; Fax: +81-6-6879-8219

E-mail: kotoku@phs.osaka-u.ac.jp; kobayasi@phs.osaka-u.ac.jp



Abstract

Biakamides A–D, novel unusually unique polyketides, were isolated from an Indonesian marine sponge (*Petrosaspongia* sp.) with a constructed bioassay using PANC-1 human pancreatic cancer cells. Through detailed analyses of the one- and two-dimensional nuclear magnetic resonance (NMR) spectra of biakamides, planar chemical structures possessing a terminal thiazole, two *N*-methyl amides, a chloromethylene, and a substituted butyryl moiety were obtained. After elucidation of the configuration of the secondary alcohol moiety in biakamides A and B, the absolute stereostructures of the two secondary methyl groups in biakamides A–D were determined by the asymmetric total syntheses of all possible stereoisomers from the optically pure monoprotected 2,4-dimethyl-1,5-diol. Biakamides A–D showed selective antiproliferative activities against PANC-1 cells cultured under glucose-deficient conditions in a

1
2
3
4
5
6 concentration-dependent manner. The primary mode of action of biakamides was found
7
8
9 to be inhibition of complex I in the mitochondrial electron transport chain.
10
11
12
13
14
15

16 **Keywords:** biakamides; polyketide; marine natural product; structure elucidation; total
17
18
19 synthesis; glucose-deficient condition; mitochondrial electron transport chain
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

The microenvironment surrounding tumors is an important target for anticancer drug discovery. Because of the disordered vascular network, solid tumors have large areas exhibiting hypoxia and/or nutrient starvation.¹ Cancer cells are known to acquire tolerance toward such severe conditions, allowing them to survive. Furthermore, these cancer cells also acquire resistance to cancer chemotherapy and irradiation and aggravate the pathology of cancer by promoting tumor growth and metastasis.² Therefore, compounds that exhibit selective growth inhibitory activity against tumor cells adapted to the tumor microenvironment may be novel, promising anticancer drugs and important chemical tools for identification of new molecule(s) responsible for the adaptation of tumor cells to hypoxia and/or nutrient starvation.

Marine natural products have been shown to be a rich and promising source of drug candidates, particularly in the field of anticancer drug discovery.^{3,4} During our assessment of bioactive substances from marine organisms, we have focused on searching for compounds targeting the tumor microenvironment. From our studies, we have identified several active compounds, such as furospinosulin-1⁵ and dictyoceratin⁶,

showing hypoxia-selective growth inhibitory activity against cancer cells. Furthermore, we have also conducted synthetic studies and target analyses of the identified compounds to validate their potential as anticancer drugs.⁷⁻¹¹

In contrast, some reports have described the search for selective growth inhibitors against cancer cells adapted to nutrient starvation conditions. According to the so-called “anti-austerity” strategy,^{12,13} several active compounds, including kigamycin D and arctigenin, have been identified from microbial secondary metabolites or traditional herbal medicines.¹⁴⁻¹⁷ However, the adaptation system of cancer cells to nutrient deprivation has not been fully elucidated. Recently, we also established a screening system to search for substances that selectively inhibit the growth of PANC-1 human pancreatic cancer cells cultured under glucose-deficient conditions, and we isolated a new 3-alkylpyridine alkaloid (*N*-methylniphatyne A) and 3,4,5-tribromo-2-(2',4'-dibromophenoxy)-phenol as active substances through bioassay-guided separation.^{18,19} Further screening of the extract library of marine organisms led us to isolate unique polyketides named biakamides A–D (**1–4**) from an Indonesian marine sponge (*Petrosaspongia* sp.).

Here, we report the isolation, structure elucidation, total synthesis, and biological evaluation of biakamides A–D (Figure 1).




Figure 1. Chemical Structures of Biakamides A (1), B (2), C (3) and D (4).

Results and Discussion

Isolation and structure elucidation of biakamides A–D

The MeOH extract (240 g) of the marine sponge *Petrosaspongia* sp. (05A01), collected in Biak, Indonesia in 2005, showed selective growth inhibitory activity against PANC-1 cells cultured in glucose-deficient medium. The MeOH extract was partitioned into an H₂O and AcOEt mixture, and the AcOEt soluble portion was further partitioned into an *n*-hexane and 90% methanol mixture. Using the bioassay, the active 90% methanol soluble portion (34 g) was fractionated by successive silica gel column

1
2
3
4
5
6 chromatography and reversed-phase high-performance liquid chromatography (HPLC)
7
8
9 to yield four active constituents, designated biakamides A (**1**, 2.8 mg), B (**2**, 1.4 mg), C
10
11
12 (**3**, 6 mg), and D (**4**, 6 mg).
13
14

15
16 The matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass
17
18 spectrometry (MS) results for biakamide A (**1**) showed pseudomolecular ion peaks at
19
20
21 m/z 534 and 536 $[M+Na]^+$ with a ratio of 3:1. These data suggested that there may be a
22
23
24 chlorine atom within this molecule. The molecular formula of **1** was determined to be
25
26
27 $C_{26}H_{42}O_3N_3SCl$ by high-resolution (HR) MALDI-TOF MS, indicating that this
28
29
30 compound possessed seven double bond equivalents. Many signals in the 1H and ^{13}C
31
32
33 NMR spectra of **1** were anomalously broadened, irrespective of solvent, and some
34
35
36 others were observed as doubled signals (Figure 2). Brief analyses of the
37
38
39 two-dimensional (2D)-nuclear magnetic resonance (NMR) spectra indicated that two
40
41
42
43
44
45 *N*-methanamide moieties were contained in the molecule, implying the presence of
46
47
48 distinguishable *cis/trans* rotamers. Thus, structure elucidation of **1** was executed using
49
50
51 the NMR signals of the respective conformers, as described below (Table 1).
52
53
54
55
56
57
58
59
60




Figure 2. ¹H and ¹³C NMR Spectra of Biakamide A (**1**).

Table 1. NMR chemical shifts of biakamide A (**1**) in CDCl₃.

| Pos. | Major conformer | | Pos. | Minor conformer ^a | |
|------|---------------------|----------------------|------|------------------------------|---------------------|
| | δ_{C} | δ_{H} | | δ_{C} | δ_{H} |
| 1 | 173.7 (br) | | 1 | | |
| 2 | 128.9 | | 2 | | |
| 3 | 138.4 (br) | 5.42 (br s) | 3 | | |
| 4 | 29.8 | 2.56 (m) | 4 | | |
| 5 | 44.2 | 1.26 (br), 1.13 (br) | 5 | | |
| 6 | 30.6 | 1.41 (br) | 6 | | |
| 7 | 34.0 | 1.42 (br), 1.18 (br) | 7 | | |
| 8 | 27.6 | 2.11 (m), 2.20 (m) | 8 | 27.5 | |
| 9 | 142.0 | | 9 | 141.5 | |
| 10 | 32.1 | 2.05 (m) | 10 | 31.8 | |
| 11 | 25.2 | 1.63 (m) | 11 | 26.1 | 1.68 (m) |
| 12 | 47.3 | 3.34 (t, 7.5 Hz) | 12 | 49.0 | 3.24 (m) |
| 13 | 14.2 (br) | 1.88 (s) | 13 | | |
| 14 | 20.0 | 0.95 (br s) | 14 | | |
| 15 | 19.8 | 0.89 (br s) | 15 | | |
| 16 | 112.4 | 5.79 (s) | 16 | 113.0 | 5.80 (s) |
| 17 | 48.5 (br) | 4.88 (s) | 17 | 52.6 (br) | |
| 18 | 167.0 (br) | | 18 | | |

| | | | | | |
|----|------------|-------------------------------|----|-----------|-------------------------------|
| 19 | 119.9 (br) | 7.33 (br) | 19 | | |
| 20 | 142.3 (br) | 7.72 (br) | 20 | | |
| 21 | 172.6 | | 21 | 172.4 | |
| 22 | 41.2 | 2.44 (m), 2.30 (m) | 22 | 40.6 | 2.46 (m), 2.28 (m) |
| 23 | 64.1 | 4.19 (m) | 23 | 64.3 | |
| 24 | 22.2 | 1.22 (d, 6.3 Hz) | 24 | 22.3 | 1.217 (d, 6.3 Hz) |
| 25 | 37.0 (br) | 3.04 (br s) | 25 | 33.3 (br) | |
| 26 | 35.2 | 2.95 (s) | 26 | 33.1 | 2.92 (s) |
| OH | | 4.59 (d, 4.3 Hz) ^b | OH | | 4.61 (d, 4.3 Hz) ^b |

^a Only distinguishable signals were indicated. ^b Observed in DMSO-*d*₆.

Analyses of the ¹³C NMR and heteronuclear single quantum coherence (HSQC) spectra of biakamide A (**1**) revealed that this molecule consisted of six methyls (four aliphatic and two nitrogen-substituted), eight methylenes (six aliphatic and two heteroatom-substituted), seven methines (two aliphatic, one oxymethine, and four olefinic), and five quaternary carbons (two olefinic and three possible carbonyls). Detailed analyses of some 2D-NMR spectra (correlation spectroscopy [COSY], HSQC, and heteronuclear multiple bond correlation [HMBC]) of **1** demonstrated the presence of seven partial structures, **A** to **G** (Figure 3). The characteristic 2-substituted thiazole structure (partial structure **A**) has been found in some marine-derived metabolites, such as barbamide or dysideathiazole.^{20,21} The chloromethylene moiety in the partial structure **E** was deduced from the HMBC correlations between H-16/C-8, C-9, and C-10 and from a comparison of the chemical shifts of the sp² carbons with those of

1
2
3
4
5
6 malyngamides and jamaicamides.^{22,23} Furthermore, the HMBC between H-13 and C-1,
7
8
9 together with an exceptionally upfield-shifted vinylic proton²⁴ (H-3, δ_{H} 5.42), indicated
10
11
12 that the two partial structures **B** and **C** were connected to form a *N*-methylated
13
14
15 α,β -unsaturated amide. The HMBCs between H-22, H-26/C-21, and H-26/C-12 led us
16
17
18 to deduce the connectivities of another terminal (structures **E–G**). Some pairs of the
19
20
21 distinguishable NMR signals corresponding to this region were observed, probably
22
23
24 because of the presence of the two conformers (ratio of approximately 3:2) for the
25
26
27
28
29 *N*-methyamide group at C-21. The nuclear Overhauser effect spectroscopy (NOESY)
30
31
32 correlation between H-22 and H-26 was observed in the spectrum of the major
33
34
35 *trans*-conformer of this *N*-methyl amide moiety, whereas the H-22/H-12 NOESY
36
37
38 correlation was observed in the minor *cis*-conformer.
39
40

41
42 In contrast, no correlation signals around the partial structure **D** were observed in
43
44
45 the HMBC and H-H COSY spectra of biakamide A (**1**). Most ^1H and ^{13}C NMR signals
46
47
48 corresponding to the left half of the molecule were exceptionally broadened, probably
49
50
51 because of the presence of a large energy barrier of bond rotation around the
52
53
54 *N*-methyamide group. Therefore, we anticipated that an elevated temperature would
55
56
57
58
59
60

1
2
3
4
5
6 accelerate bond rotation to yield averaged and sharpened NMR signals. As expected, the
7
8
9 ^1H NMR spectrum of **1** measured at 50°C in DMSO- d_6 gave somewhat sharpened
10
11
12 signals. Under this condition, the magnetization relay (from H-15 to H-4, H-5, H-7, and
13
14
15 H-8) was observed in the total correlation spectroscopy (TOCSY) results. Furthermore,
16
17
18 the HMBCs between H-15/C-5 and C-7 were observed under these conditions,
19
20
21 providing evidence for the connectivities between the partial structures **C**, **D**, and **E**.
22
23
24
25 The geometries of the two olefins (Δ^2 and $\Delta^{9(16)}$) were determined as *E* from the
26
27
28 NOESY correlations among H-13/H-4, H-16/H-10, and H-11. Finally, the absolute
29
30
31 configuration of the secondary alcohol moiety at C-23 was found to be *S* by applying
32
33
34 the modified Mosher method²⁵ (Figure 4, Supporting Information). In this way, most of
35
36
37 the chemical structure of biakamide A (**1**), except for configurations of the two
38
39
40 secondary methyls at C-4 and C-6, could be determined as depicted in Figure 4.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3. Partial Structures and 2D NMR correlations of Biakamide A (**1**).




Figure 4. Selected NOEs and Modified Mosher Analysis of Biakamide A (**1**).

From the HR-MALDI-TOF MS analysis, the molecular formula of biakamide B (**2**) was found to be the same as that of biakamide A (**1**). The one-dimensional (1D) and 2D NMR analyses revealed that biakamide B (**2**) possessed almost the same planar structure as **1**, except for the geometry of the chloromethylene moiety, in which the NOESY correlations between H-16/H-7 and H-8 were observed to define the geometry

of the $\Delta^{9(16)}$ olefin as *Z* (Figure 5).

The molecular formula of biakamide C (**3**) was determined to be $C_{27}H_{42}O_3N_3SCl$, by HR-MALDI-TOF MS. Initial attempts to determine the structure of **3** revealed that many signals in the 1H -NMR spectrum of **3** were further broadened compared with those of **1**. Additionally, compound **3** was unstable and gradually changed to another compound during prolonged NMR measurement in $CDCl_3$ solvent. Considering the acid lability of **3**, the $CDCl_3$ that passed through basic alumina just before preparation of the NMR sample was used to suppress the decomposition of **3**. Then, the chemical structure of **3** could be deduced by detailed analysis of the 2D NMR spectra, which was similar to that of **1**, except that a methoxy group (δ_H 3.60) and an olefinic proton (δ_H 5.15) were observed in the terminal acyl moiety. Through analysis of HMBCs (H-22/C-21 and C-23, H-24/C-22 and C-23, and H-27/C-23), as depicted in Figure 5, biakamide C (**3**) was found to possess a 3-methoxy-2-butenoyl moiety at its terminal. Some reported metabolites, such as ajudazole,²⁶ also had the same functionality. Furthermore, the geometry of the Δ^{22} olefin in **3** was determined as *E* from nuclear Overhauser effect (NOE) experiments. Additionally, biakamide D (**4**) was assigned as the geometrical

counterpart of biakamide C (**3**) at the $\Delta^{9(16)}$ chloromethylene moiety (Figure 5).




Figure 5. Planar Structures and Selected NOEs of Biakamides B (**2**), C (**3**) and D (**4**).

Total syntheses of biakamides A–D (**1–4**)

Finally, we aimed to determine the relative/absolute stereostructures of the two secondary methyl groups at C-4 and C-6 for biakamides A–D (**1–4**). As described above, the 1H NMR signals at the C-4–C-7 positions in biakamides were too broadened, and we could not apply empirical methods^{27, 28} to analyze the differences in 1H NMR chemical shifts. Accordingly, we decided to carry out the total synthesis of **1–4** in order to determine the absolute stereostructures of these moieties and to generate sufficient

amounts of the compounds for further biological analyses.

An outline of our synthetic plan is depicted in Figure 6. To obtain all possible stereo-isomers of biakamides A–D (**1–4**), we planned to use the monoprotected 2,4-dimethyl-1,5-pentanediol as a chiral synthon, which could be obtained in an optically pure form through the known enzymatic desymmetrization and kinetic resolution of the *syn*-isomer and *anti*-isomer, respectively.²⁹ The central polyketide skeleton **II** could be prepared through the Corey-Seebach coupling reaction³⁰ between the 1,3-dithiane **III** and the nitrogen-contained alkyl halide, and the following successive introduction of the unsaturated amide and chloromethylene moieties was expected to provide the common precursor **I** of biakamides. The final acylation using the corresponding carboxylic acid would afford biakamides A–D (**1–4**).





Figure 6. Retrosynthesis of Biakamides.

Initially, the syntheses of biakamides C (**3**) and D (**4**) were carried out as shown in Scheme 1 because the structure determination process for **3** and **4** was expected to be simpler. The (*R, R*)-2,4-dimethyl-1,5-pentanediol ((-)-**5**) was prepared by the known enzymatic optical resolution method²⁹ using lipase AK. According to a recent report,³¹ monoprotection of the two hydroxyl groups of (-)-**5** as *tert*-butyldiphenylsilyl (TBDPS) ether was achieved in acceptable yield. Subsequent one-pot TEMPO oxidation/Wittig

1
2
3
4
5
6 reaction³² proceeded smoothly to give an unsaturated ester (**7**). The double bond of **7**
7
8
9 was reduced by treatment with magnesium in MeOH, and the subsequent hydrolysis of
10
11
12 the resulting ester (**8**) provided a carboxylic acid (**9**). Then, **9** was converted into the
13
14
15 corresponding Weinreb amide (**10**), which was reduced with DIBAL to give an
16
17
18 aldehyde (**11**). Treatment of **11** with 1,3-propanedithiol and a catalytic amount of
19
20
21 iodine³³ gave a 1,3-dithiane (**12**), the designated precursor **III** of the central fragment.
22
23
24 As expected, the Corey-Seebach coupling reaction between a carbanion generated by
25
26
27 the *n*-BuLi treatment of **12** and an alkyl iodide (**21**)³⁴, followed by TBAF treatment,
28
29
30 afforded the desired compound (**13**) in good yield. TPAP oxidation of the liberated
31
32
33 primary alcohol of **13** gave an aldehyde (**14**), and the subsequent Wittig homologation
34
35
36 with a stabilized ylide yielded an α,β -unsaturated ester (**15**). The concomitant *Z*-isomer
37
38
39 was separated by SiO₂ column chromatography. Subsequent hydrolysis of the ester
40
41
42 moiety with NaOH or KOH in aqueous methanol or 1,4-dioxane was found to be very
43
44
45 sluggish, whereas TMSOK treatment³⁵ resulted in decomposition. Gratifyingly,
46
47
48 hydrolysis with LiOH proceeded efficiently to provide a carboxylic acid (**16**) in good
49
50
51
52
53
54
55
56
57
58
59
60 yield. Epimerization at C-4, the γ -position of the unsaturated ester moiety, did not occur


1
2
3
4
5
6 during hydrolysis. Subsequent condensation with a secondary amine (**22**)³⁶ yielded an
7
8
9 *N*-methanamide (**17**). We found that almost all the signals in the ¹H NMR spectrum of
10
11
12 the amide **17** broadened exceptionally, whereas the normal and sharp signals were
13
14
15 observed in the ¹H NMR spectrum of the acid **16**. These data clearly indicated that the
16
17
18 presence of the unsaturated *N*-methanamide moiety interrupted free bond rotation.
19
20
21 Iodine treatment of **17** under basic conditions resulted in clean removal of 1,3-dithiane
22
23
24 to give a ketone (**18**), and subsequent introduction of chloromethylene moiety was
25
26
27 quantitatively proceeded to give **19** through the Wittig reaction using
28
29
30 (chloromethyl)triphenylphosphonium chloride (*E/Z* = 3:2). Finally, removal of the Boc
31
32
33 moiety by TFA treatment and subsequent condensation with a known
34
35
36 *E*-3-methoxy-2-butenic acid (**23**)³⁷ afforded (4*R*, 6*S*)-biakamides C (**3**) and D (**4**).
37
38
39
40
41
42 These two compounds were separated by reversed-phase HPLC under the established
43
44
45 conditions.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Scheme 1. Total Synthesis of (4*R*,6*S*)-Biakamides **C** (**3**) and **D** (**4**). Reagents and Conditions: (a) TBDPSCl, Et₃N, CH₃CN/Hexane, 50%; (b) TEMPO, PhI(OAc)₂, CH₂Cl₂; (c) Ph₃P=CHCO₂Me, toluene, 100 °C, 82% (2 steps); (d) Mg, MeOH, quant.; (e) LiOH, MeOH, 96%; (f) MeONHMe·HCl, EDCI·HCl, HOBT, Et₃N, CH₂Cl₂; (g) DIBAL, THF, 0 °C, 49% (2 steps); (h) 1,3-propanedithiol, I₂, CHCl₃, 90%; (i) **21**, *n*-BuLi, THF; (j) TBAF, THF, 61% (2 steps); (k) TPAP, NMO, MS4A, CH₂Cl₂, 79%; (l) Ph₃P=C(Me)CO₂Et, toluene, 100 °C, quant.; (m) LiOH, THF/MeOH/H₂O, 77%; (n) **22**, EDCI·HCl, HOBT, Et₃N, CH₂Cl₂, 92%; (o) I₂, NaHCO₃, aq. CH₃CN, 0 °C, 47%; (p) (chloromethyl)triphenylphosphonium chloride, LHMDs, THF, 99%; (q) TFA, CH₂Cl₂; (r) **23**, EDCI·HCl, HOBT, Et₃N, CH₂Cl₂, 78%; (s) HPLC separation.

According to the synthetic route described above, (4*R*, 6*R*)-biakamides C (**3'**) and D (**4'**) were synthesized starting from (2*S*, 4*R*)-2,4-dimethyl-1,5-pentanediol 5-TBDPS ether (**6'**) (Scheme 2).³⁸ Each reaction proceeded without problem, resulting in comparable yields. A comparison of the ¹H-NMR spectra of these compounds revealed

that the ^1H signals of the natural biakamide C (**3**) showed good accordance with those of the (4*R*, 6*S*)-isomer, whereas some discrepancies were observed with those of the (4*R*, 6*R*)-isomer, typically at H-6 and H-7 signals (Figure 7). Furthermore, the specific rotation ($[\alpha]_{\text{D}} = -17.2$) of the (4*R*, 6*S*)-isomer matched well with that ($[\alpha]_{\text{D}} = -18.0$) of the natural biakamide C (**3**). Similar results were obtained in the case of biakamide D (**4**) (data not shown). Therefore, the absolute stereostructures both of biakamides C (**3**) and D (**4**) were unambiguously determined to be (4*R*, 6*S*), as shown in Figure 1.



Scheme 2. Synthesis of (4*R*,6*R*)-Biakamides C (**3'**) and D (**4'**).





Figure 7. Comparison of ^1H NMR Spectra of Natural biakamide C (**3**) and Synthetic $(4R,6S)$ -**3** or $(4R,6R)$ -**3'**.

Next, the synthesis of biakamides A (**1**) and B (**2**) was also investigated. The ^{23}S configuration for these two compounds was determined as described above. However, a comparison of the NMR spectra and specific rotations between the four synthetic stereoisomers [$(4R, 6S)$ -, $(4S, 6R)$ -, $(4S, 6S)$ -, and $(4R, 6R)$ -] and the natural biakamides A (**1**) and B (**2**) is needed to finalize this stereochemical analysis.

In the same manner as described above, the $(4S, 6R)$ - and $(4S, 6S)$ -isomers of the amine **20** were synthesized starting from the $(2S, 4S)$ - or $(2R, 4S)$ -congeners of the

2,4-dimethyl-1,5-pentanediol 5-TBDPS ether, respectively. Condensation between commercially available (*S*)-3-hydroxybutyric acid and the respective isomer of the amine **20** proceeded without problem, and subsequent HPLC separation afforded all possible stereoisomers of biakamides A (**1**) and B (**2**) (Scheme 3).



Scheme 3. Synthesis of All Possible Isomers of Biakamides A (**1**) and B (**2**).

Next, we compared the NMR spectra and specific rotations of the four diastereomers with those of the natural biakamide A (**1**) (Figure 8). The potential (4*S*,

6*S*) and (4*R*, 6*R*) configurations were easily excluded by considering the obvious differences in the chemical shifts of the ¹H-NMR signals at H-6 and H-7 between the isomers and the natural biakamide A (**1**) (Figure 8A). In contrast, the ¹H-NMR spectra of the (4*S*, 6*R*)- and (4*R*, 6*S*)-isomers were found to similar to each other throughout the molecule. Fortunately, only the multiplicity of the signals at H-12 of the (4*S*, 6*R*)-isomer was different from that of the (4*R*, 6*S*)-isomer and the natural biakamide A (**1**) (Figure 8B). In addition, the specific rotation of the natural biakamide A (**1**) ($[\alpha]_D = +6.3$) was similar to that of the (4*R*, 6*S*)-isomer ($[\alpha]_D = +1.2$), whereas a large value ($[\alpha]_D = +33.4$) was observed in the case of the (4*S*, 6*R*)-isomer.




Figure 8. Comparison of ^1H NMR Spectra of Natural biakamide A (**1**) and Synthetic four isomers of **1**.

Furthermore, crucial evidence was obtained from a comparison of the CD spectra of these compounds. Thus, the CD spectrum of the (4*S*, 6*R*)-isomer showed a positive maximum at 210 nm derived from the α,β -unsaturated amide moiety, whereas both the (4*R*, 6*S*)-isomer and natural biakamide A (**1**) showed a negative maximum (Figure 9). Similar data were obtained in the case of biakamide B (**2**) (data not shown). Thus, the absolute stereochemistry both of biakamides A (**1**) and B (**2**) was found to be (4*R*, 6*S*), which was similar to those of biakamides C (**3**) and D (**4**).




Figure 9. Comparison of CD Spectra of Natural biakamide A (1) and Synthetic (4*R*,6*S*)-1 or (4*S*,6*R*)-1.

Bioactivity of biakamides A–D (1–4)

Biakamides A–D (1–4) exhibited selective antiproliferative activity against PANC-1 cells cultured under glucose-deficient conditions, in a concentration-dependent manner

(Table 2). Among the four compounds, biakamides C (3) and D (4) showed more potent activity, with a half-maximal inhibitory concentration (IC_{50}) of 0.5 μ M. Additionally, when used at a concentration of less than 30 μ M, these biakamides showed almost no toxicity against PANC-1 cells cultured in normal medium containing 25 mM glucose. These data indicated that these biakamides may be promising anticancer drugs and that the anticancer effects of these compounds were realized by the targeting of cancer cells adapted to a glucose-deficient microenvironment.

Table 2. Growth inhibition of biakamides A (1) – D (4) against PANC-1 cells.

| | 1 | | 2 | | 3 | | 4 | |
|-------------|-----------|------|-----------|------|-----------|------|-----------|------|
| | IC_{50} | S.I. | IC_{50} | S.I. | IC_{50} | S.I. | IC_{50} | S.I. |
| Glucose (-) | 1.0 | - | 4.0 | - | 0.5 | - | 0.5 | - |
| Glucose (+) | >100 | >100 | >100 | >25 | 50 | 100 | 35 | 70 |

IC_{50} = μ M; S.I = selective index: IC_{50} in Glucose (+) medium / IC_{50} in Glucose (-) medium.

Next, we performed a mechanistic analysis of biakamides. Recent studies have revealed that cancer cells adapt to nutrient starvation by activating the phosphoinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway and the unfolded protein response (UPR), such as induction of glucose-regulated protein 78

(GRP78). Moreover, inhibitors of mitochondrial function or GRP78 are known to exhibit selective growth-inhibitory activity against cancer cells cultured under glucose-deprived conditions.^{39,40} Indeed, we recently revealed that 3,4,5-tribromo-2-(2',4'-dibromophenoxy)-phenols exhibit antiproliferative activity against PANC-1 cells cultured under glucose-starved conditions through weak inhibition of Akt phosphorylation and GRP78 expression. We clarified that the antiproliferative activity of this compound may be mediated by inhibition of complex II in the mitochondrial electron transport chain.¹⁹ We then analyzed the effect of biakamides on these signaling pathways or mitochondrial function using western blotting and Mito Check Complex Activity Assays (Cayman Chemical).

Western blot analysis revealed that Akt phosphorylation and GRP78 expression were induced in PANC-1 cells cultured in glucose-deficient medium in comparison with those cultured in general glucose medium (Figure 10, lanes 1 and 2). Additionally, biakamide C (**3**) weakly inhibited Akt phosphorylation and GRP78 expression in PANC-1 cells cultured in glucose-deficient medium (lanes 5 and 6). A similar phenomenon was observed for antimycin A, a known anti-austerity agent that inhibits

1
2
3
4
5
6 complex III in the mitochondrial electron transport chain (lanes 3 and 4).
7
8

9
10 Furthermore, we found that biakamide C (**3**) selectively inhibited complex I in the
11
12 mitochondrial electron transport chain, with an IC_{50} of 0.45 μ M. This inhibitory
13
14 concentration was similar to the IC_{50} of the antiproliferative activity of **3** against
15
16 PANC-1 cells cultured under glucose-deficient conditions, as shown in Table 3. We
17
18
19 also found that rotenone, a known inhibitor of complex I, also exhibited selective
20
21
22 growth inhibitory activity against PANC-1 cells cultured under glucose-deficient
23
24
25 conditions and showed inhibitory properties similar to those observed for Akt and
26
27
28 GRP78 (Figure S1, Supporting Information). These results strongly implied that
29
30
31 biakamide C (**3**) showed selective growth inhibitory activity against cancer cells
32
33
34 adapted to glucose-deficient conditions through inhibition of complex I in the
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
mitochondrial electron transport chain.




Figure 10. Effect of biakamide C (**3**) on the Akt signaling and induction of GRP78 by western blot analysis. The PANC-1 cells cultured in the Glucose Deficient Medium (Glucose (—)) or General Glucose Medium (Glucose (+)) were treated with biakamide C (**3**) or antimycin A. Cell lysate was resolved by using SDS-PAGE and detected with antibodies against the indicated proteins.

Table 3. Effect of biakamide C (**3**) on the mitochondrial electron transfer chain.

| | IC ₅₀ value (μM) | | | | |
|-------------------------------|-----------------------------|------------|----------------|------------|-----------|
| | complex I | complex II | complex II/III | complex IV | complex V |
| biakamide C (3) | 0.45 | >100 | >100 | >100 | 37 |
| positive control ^a | 0.13 | 18 | 0.003 | 7.7 | 0.36 |

^a Compounds used as positive control are rotenone, thenoyltrifluoroacetone, antimycin A, KCN and oligomycin for complex I, II, III, IV and V, respectively.

Conclusion

Based on the constructed bioassay, we isolated four novel polyketides, designated biakamides A–D (**1–4**), from the Indonesian marine sponge (*Petrosaspongia* sp.), as selective growth inhibitors against the PANC-1 human pancreatic cancer cells cultured

under glucose-deprived conditions. The unique chemical structures of these compounds could be unambiguously elucidated by spectral analyses and the asymmetric total syntheses of all possible stereoisomers.

The primary mode of action of biakamides was found to be inhibition of complex I in the mitochondrial electron transport chain. Further biological evaluation, including *in vivo* studies, mechanistic analyses, and structure-activity relationship studies using the synthetic analogs, are now underway.

Experimental Section

General experimental

The following instruments were used to obtain physical data: a JASCO P-2200 digital polarimeter (L = 50 mm) for specific rotations; a JEOL ECS-300 (^1H -NMR: 300 MHz, ^{13}C -NMR: 75 MHz), ECA-500 (^1H -NMR: 500 MHz, ^{13}C -NMR: 125 MHz) and an Agilent NMR system (^1H -NMR: 600 MHz, ^{13}C -NMR: 150 MHz) spectrometer for ^1H and ^{13}C NMR data using tetramethylsilane as an internal standard; a JASCO FT/IR-5300 infrared spectrometer for IR spectra; a JEOL JMS-S3000 mass spectrometer for MALDI-TOF MS; a Waters Q-ToF Ultima API mass spectrometer for ESI-TOF MS. Silica gel (Kanto, 40-100 μm) and pre-coated thin layer chromatography (TLC) plates (Merck, 60F₂₅₄) were used for column chromatography and TLC. Spots on

TLC plates were detected by spraying acidic *p*-anisaldehyde solution (*p*-anisaldehyde: 25 mL, *c*-H₂SO₄: 25 mL, AcOH: 5 mL, EtOH: 425 mL) or phosphomolybdic acid solution (phosphomolybdic acid: 25 g, EtOH: 500 mL) with subsequent heating. Unless otherwise noted, all the reaction was performed under a N₂ atmosphere. After workup, the organic layer was dried over Na₂SO₄.

Extraction and isolation of active compounds

The dried marine sponge of *Petrosaspongia* sp. (2.4 kg), which was collected in 2005 at Biak, Indonesia, was extracted with MeOH. On the guidance of bioassay, the MeOH extract (240 g, IC₅₀ (Glucose Deficient Medium) = 50 µg/mL, IC₅₀ (General Glucose Medium) = >100 µg/mL) was partitioned into a water-EtOAc mixture (1:1). The active EtOAc soluble portion was further partitioned into a hexane-90%MeOH mixture (1:1). The active 90%MeOH soluble portion [34 g, IC₅₀ (Glucose Deficient Medium) = 10 µg/mL, IC₅₀ (General Glucose Medium) = >30 µg/mL] was fractionated by SiO₂ gel column chromatography [CHCl₃-MeOH-H₂O (lower phase)] to give six fractions (Fr. 1- Fr. 6). The active Fr. 2 [6.3 g, IC₅₀ (Glucose Deficient Medium) = 5 µg/mL, IC₅₀ (General Glucose Medium) = 30 µg/mL] was fractionated by SiO₂ gel column chromatography [CHCl₃-MeOH-H₂O (lower phase)] to give six fractions (Fr. 2-1 - Fr. 2-6). The active Fr. 2-5 was then further purified by ODS HPLC (Cosmosil MS-II, CH₃CN-H₂O = 55:45) to obtain six fractions (Fr. 2-5-1 - Fr. 2-5-6). As a result of bioassay, the Fr. 2-5-2 and the Fr. 2-5-4 showed the cytotoxic activity against PANC-1 cell in the Glucose Deficient Medium selectively. Then, the Fr. 2-5-2 (7.4 mg) was then

further purified by ODS HPLC (Cosmosil MS-II, MeOH-H₂O = 6:4) to afford biakamide A (**1**, 2.8 mg) and biakamide B (**2**, 1.4 mg). And the Fr. 2-5-4 (21.1 mg) was then further purified by ODS HPLC (Cosmosil MS-II, MeOH-H₂O = 7:3) to afford biakamide C (**3**, 6.1 mg) and biakamide D (**4**, 6.3 mg).

Biakamide A (**1**): Colorless amorphous powder.

$[\alpha]_D^{20} +6.3$ ($c = 0.22$, CHCl₃).

MALDI-TOF-MS m/z : 534 [M+Na]⁺.

HR-MALDI-TOF-MS: Calcd for C₂₆H₄₂N₃O₃SClNa 534.25276. Found 534.25333.

UV λ_{\max} (MeOH) nm (ϵ): 242 (13200).

IR ν_{\max} (KBr) cm⁻¹: 3611, 2926, 1628, 1456, 1397.

¹H NMR (600 MHz, δ_H), ¹³C NMR (150 MHz, δ_C): Table 1

Biakamide B (**2**): Colorless amorphous powder.

$[\alpha]_D^{20} +11.9$ ($c = 0.09$, CHCl₃).

MALDI-TOF-MS m/z : 534 [M+Na]⁺.

HR-MALDI-TOF-MS: Calcd for C₂₆H₄₂N₃O₃SClNa 534.25276. Found 534.25310.

UV λ_{\max} (MeOH) nm (ϵ): 240 (11200).

IR ν_{\max} (KBr) cm⁻¹: 3561, 2926, 1624, 1458, 1397.

¹H NMR (600 MHz, δ_H), ¹³C NMR (150 MHz, δ_C): Table S1

Biakamide C (**3**): Colorless amorphous powder.

$[\alpha]_D^{20} -18.0$ ($c = 0.40$, CHCl₃).

MALDI-TOF-MS m/z : 546 [M+Na]⁺.

HR-MALDI-TOF-MS: Calcd for C₂₇H₄₂N₃O₃SClNa 546.25276. Found 546.25260.

UV λ_{\max} (MeOH) nm (ϵ): 255 (10043).

IR ν_{\max} (KBr) cm^{-1} : 2953, 2926, 1720, 1640, 1501, 1454, 1393.

^1H NMR (600 MHz, δ_{H}), ^{13}C NMR (150 MHz, δ_{C}): Table S2

Biakamide D (**4**): Colorless amorphous powder.

$[\alpha]_{\text{D}}^{20} -18.4$ ($c = 0.41$, CHCl_3).

MALDI-TOF-MS m/z : 546 $[\text{M}+\text{Na}]^+$.

HR-MALDI-TOF-MS: Calcd for $\text{C}_{27}\text{H}_{42}\text{N}_3\text{O}_3\text{SClNa}$ 546.25276. Found 546.25309.

UV λ_{\max} (MeOH) nm (ϵ): 258 (11875).

IR ν_{\max} (KBr) cm^{-1} : 2955, 2928, 1647, 1456, 1381, 1240, 1146, 1074.

^1H NMR (600 MHz, δ_{H}), ^{13}C NMR (150 MHz, δ_{C}): Table S3

Preparation of (*S*)- or (*R*)-MTPA ester of **1** and **2**:

(*S*)- or (*R*)-MTPA (20 equiv.), DMAP (5 equiv.), DCC (20 equiv.) were added to a solution of **1** or **2** in THF, and the whole mixture was stirred for 4 days. Sat. NaHCO_3 aq. was added to the mixture and the whole mixture was extracted with AcOEt. Removal of the solvent from AcOEt extract under reduced pressure gave a crude product, which was purified by SiO_2 column [hexane/AcOEt = 1:1 \rightarrow $\text{CHCl}_3/\text{MeOH}/\text{H}_2\text{O}$ = 30:3:1 (lower phase)], and by reversed-phase HPLC (Cosmosil 5C₁₈-MS-II, 10 mm i.d. \times 250 mm, $\text{CH}_3\text{CN}/\text{H}_2\text{O}$ = 55:45 \rightarrow 70:30 \rightarrow 80:20, flow rate = 4.0 mL/min, detection UV = 240 nm) to give the corresponding MTPA esters.

(*S*)-MTPA ester of **1**:

^1H NMR (600 MHz, CDCl_3 : only key resonances of the major conformer are listed):

δ 5.64 (1H, m, H-23), 2.93 (3H, s, H-26), 2.78, 2.44 (total 2H, m, H-22), 1.37 (3H, d, J = 6.2 Hz, H-24).

(*R*)-MTPA ester of **1**:

¹H NMR (600 MHz, CDCl₃: only key resonances of the major conformer are listed):

δ 5.63 (1H, m, H-23), 2.87 (3H, s, H-26), 2.74, 2.41 (total 2H, m, H-22), 1.45 (3H, d, *J* = 6.3 Hz, H-24).

HR-ESI-TOF-MS: Calcd for C₃₆H₄₉N₃O₅F₃NaSCl 750.2931. Found 750.2968.

(*S*)-MTPA ester of **2**:

¹H NMR (600 MHz, CDCl₃: only key resonances of the major conformer are listed):

δ 5.64 (1H, m, H-23), 2.95 (3H, s, H-26), 2.78, 2.44 (total 2H, m, H-22), 1.37 (3H, d, *J* = 6.2 Hz, H-24).

HR-ESI-TOF-MS: Calcd for C₃₆H₄₉N₃O₅F₃NaSCl 750.2931. Found 750.2968.

(*R*)-MTPA ester of **2**:

¹H NMR (600 MHz, CDCl₃: only key resonances of the major conformer are listed):

δ 5.64 (1H, m, H-23), 2.89 (3H, s, H-26), 2.75, 2.42 (total 2H, m, H-22), 1.45 (3H, d, *J* = 6.3 Hz, H-24).

HR-ESI-TOF-MS: Calcd for C₃₆H₄₉N₃O₅F₃NaSCl 750.2931. Found 750.2978.

Total synthesis of biakamides A - D

(*2R,4R*)-2,4-Dimethylpentane-1,5-diol (**5**)

The compound was obtained through the reported method.²⁹ The optical purity was confirmed by NMR measurement of the corresponding bis-(*R*)-MTPA ester.

(*2R,4R*)-5-((*tert*-Butyldiphenylsilyl)oxy)-2,4-dimethylpentan-1-ol (**6**)

Et₃N (575 mL, 4.1 mmol, 1.2 equiv.) and TBDPSCl (894 mL, 3.4 mmol, 1.0 equiv.)

were added to a solution of **5** (454.4 mg, 3.4 mmol) in CH₃CN / Hexane (3:1, 34 mL), and the whole mixture was stirred for 19 h at rt. Sat. NaHCO₃ aq. was added to the mixture, and the whole mixture was extracted with AcOEt. Removal of the solvent from AcOEt extract under reduced pressure gave a crude product, which was purified by SiO₂ column (Hexane/AcOEt = 5:1 to 1:1) to give **6** (636 mg, 50%) as a colorless oil. The spectroscopic and physical data were identical to those reported.⁴¹

Methyl (4*R*,6*R*,*E*)-7-((*tert*-butyldiphenylsilyl)oxy)-4,6-dimethylhept-2-enoate (7**)**

Iodobenzene diacetate (1.22 g, 2.8 mmol, 2.3 equiv.) and TEMPO (25.6 mg, 0.17 mmol, 0.1 equiv.) were added to a solution of **7** (607 mg, 1.6 mmol) in CH₂Cl₂, and the whole mixture was stirred for 3 h at rt. Then toluene (30 mL) and methyl 2-(triphenyl-λ⁵-phosphanylidene)acetate (658 mg, 2.0 mmol, 1.2 equiv.) was added to the mixture, and the whole mixture was stirred for 28 h at 100 °C. Na₂S₂O₃ / NaHCO₃ aq. was added to the mixture, and the whole mixture was extracted with AcOEt. The AcOEt extract was successively washed with sat. NH₄Cl aq., NaHCO₃ aq., and brine. Removal of the solvent from the AcOEt extract under reduced pressure gave a crude product, which was purified by SiO₂ column (Hexane/AcOEt = 15:1) to give **7** (571 mg, 82%) as a colorless oil.

[α]_D²⁶ -21.9 (*c* 1.17, CHCl₃). ¹H-NMR (600 MHz, CDCl₃) δ: 7.66 (4H, t, *J* = 6.5 Hz), 7.45-7.38 (6H, m), 6.86 (1H, dd, *J* = 15.8, 7.9 Hz), 5.71 (1H, d, *J* = 15.8 Hz), 3.73 (3H, s), 3.50 (1H, dd, *J* = 9.7, 5.2 Hz), 3.44 (1H, dd, *J* = 9.7, 6.1 Hz), 2.32 (1H, quint, *J* = 7.0 Hz), 1.69 (1H, q-like, *J* = 6.3 Hz), 1.46 (1H, dt, *J* = 13.7, 6.9 Hz), 1.18 (1H, dt, *J* = 13.7,

7.1 Hz), 1.06 (9H, s), 0.99 (3H, d, $J = 6.5$ Hz), 0.92 (3H, d, $J = 6.8$ Hz). ^{13}C -NMR (150 MHz, CDCl_3) δ : 167.4, 155.3, 135.62 (2C), 135.60 (2C), 133.9, 133.8, 129.6 (2C), 127.6 (4C), 119.0, 68.4, 51.4, 39.5, 34.1, 33.2, 26.9 (3C), 19.5, 19.3, 17.3. IR (KBr): 2957, 1725, 1657, 1429, 1111 cm^{-1} . MS (ESI-TOF) m/z : 447 $[\text{M}+\text{Na}]^+$. HRMS (ESI-TOF) m/z : 447.2331 calcd for $\text{C}_{26}\text{H}_{36}\text{O}_3\text{SiNa}$; Found: 447.2321.

Methyl (4*S*,6*R*)-7-((*tert*-butyldiphenylsilyl)oxy)-4,6-dimethylheptanoate (8)

Magnesium (160 mg, 6.6 mmol, 5.0 equiv.) was added to a solution of **7** (557 mg, 1.3 mmol) in MeOH (10 mL), and whole mixture was stirred for 1 h at rt. Sat. NH_4Cl aq. was added to the mixture, and the whole mixture was extracted with AcOEt, and the AcOEt extract was washed with Sat. NH_4Cl aq. and brine. Removal of the solvent from the AcOEt extract under reduced pressure gave a crude product, which was purified by SiO_2 column (Hexane/AcOEt = 10:1) to give **8** (559 mg, quant.) as a colorless oil. $[\alpha]_{\text{D}}^{27} +9.5$ (c 1.39, CHCl_3). ^1H -NMR (600 MHz, CDCl_3) δ : 7.67 (4H, d, $J = 6.7$ Hz), 7.44-7.37 (6H, m), 3.66 (3H, s), 3.47 (1H, dd, $J = 9.7, 5.9$ Hz), 3.43 (1H, dd, $J = 9.7, 6.2$ Hz), 2.35-2.23 (2H, m), 1.76-1.71 (1H, m), 1.62-1.57 (1H, m), 1.50-1.42 (2H, m), 1.24-1.20 (1H, m), 1.06 (9H, s), 1.06-1.02 (1H, m), 0.88 (3H, d, $J = 6.7$ Hz), 0.84 (3H, d, $J = 6.1$ Hz). ^{13}C -NMR (150 MHz, CDCl_3) δ : 174.5, 135.6 (4C), 134.04, 134.03, 129.5 (2C), 127.6 (4C), 69.4, 51.5, 40.3, 33.1, 32.7, 31.9, 29.7, 26.9 (3C), 19.3, 19.1, 16.6. IR (KBr): 2956, 1740, 1428, 1111 cm^{-1} . MS (ESI-TOF) m/z : 449 $[\text{M}+\text{Na}]^+$. HRMS (ESI-TOF) m/z : 449.2488 calcd for $\text{C}_{26}\text{H}_{38}\text{O}_3\text{SiNa}$; Found: 449.2486.

(4*S*,6*R*)-7-((*tert*-Butyldiphenylsilyl)oxy)-4,6-dimethylheptanoic acid (9)

LiOH (153 mg, 6.6 mmol, 5.0 equiv.) was added to a solution of **8** (543 mg, 1.3 mmol) in MeOH (10 mL), and the whole mixture was stirred for 7 h at rt. 5% HCl was added to the mixture, and the whole mixture was extracted with AcOEt. Removal of the solvent from the AcOEt extract under reduced pressure gave a crude product, which was purified by SiO₂ column (Hexane/AcOEt = 2:1) to give **9** (504 mg, 96%) as a colorless oil.

$[\alpha]_D^{26} +9.9$ (*c* 0.37, CHCl₃). ¹H-NMR (600 MHz, CDCl₃) δ : 7.66 (4H, d, *J* = 6.8 Hz), 7.43-7.36 (6H, m), 3.47 (1H, dd, *J* = 9.7, 5.9 Hz), 3.43 (1H, dd, *J* = 9.7, 6.3 Hz), 2.38-2.27 (2H, m), 1.76-1.70 (1H, m), 1.63-1.58 (1H, m), 1.50-1.42 (2H, m), 1.25-1.20 (1H, m), 1.06 (9H, s), 1.06-1.02 (1H, m), 0.88 (3H, d, *J* = 6.8 Hz), 0.84 (3H, d, *J* = 6.2 Hz). ¹³C-NMR (150 MHz, CDCl₃) δ : 179.5, 135.6 (4C), 134.0 (2C), 129.5 (2C), 127.6 (4C), 69.4, 40.3, 33.1, 32.4, 31.6, 29.6, 26.9 (3C), 19.3, 19.0, 16.6. IR (KBr): 3300, 2858, 1709, 1428, 1111 cm⁻¹. MS (ESI-TOF) *m/z*: 435 [M+Na]⁺. HRMS (ESI-TOF) *m/z*: 435.2331 calcd for C₂₅H₃₆O₃SiNa; Found: 435.2340.

(4*S*,6*R*)-7-((*tert*-Butyldiphenylsilyl)oxy)-4,6-dimethylheptanal (11)

HOBt (229 mg, 1.7 mmol, 1.4 equiv.), MeONHMe•HCl (165 mg, 1.7 mmol, 1.4 equiv.), Et₃N (0.85 mL, 6.1 mmol, 5.0 equiv.) and EDCI•HCl (325 mg, 1.7 mmol, 1.4 equiv.) were added to a solution of **9** (499 mg, 1.2 mmol) in CH₂Cl₂ (20 mL), and the whole mixture was stirred for 3 h at rt. Sat. NH₄Cl aq. was added to the mixture, and the whole mixture was extracted with AcOEt, and the AcOEt extract was washed with Sat.

NH₄Cl aq., NaHCO₃ aq., and brine. Removal of the solvent from the AcOEt extract under reduced pressure gave crude Weinreb amide **10**, which was used in the next reaction without further purification. The crude **10** was dissolved in anhydrous THF (12 mL). DIBAL-H solution (1.0 M in THF, 1.4 mL, 1.4 mmol, 1.2 equiv.) was added to the solution at 0 °C, and the whole mixture was stirred for 1 h at 0 °C. Sat. NH₄Cl aq. was added to the mixture, and the whole mixture was extracted with AcOEt, and the AcOEt extract was washed with sat. NH₄Cl aq. and brine. Removal of the solvent from the AcOEt extract gave a crude product, which was purified by SiO₂ column (Hexane/AcOEt = 12:1) to give **11** (226 mg, 0.58 mmol, 49%) as a colorless oil.

$[\alpha]_D^{26} +10.1$ (*c* 1.79, CHCl₃). ¹H-NMR (600 MHz, CDCl₃) δ : 9.76 (1H, s), 7.68 (4H, d, *J* = 7.0 Hz), 7.44-7.38 (6H, m), 3.49 (1H, dd, *J* = 9.7, 5.9 Hz), 3.45 (1H, dd, *J* = 9.7, 6.5 Hz), 2.46-2.35 (2H, m), 1.78-1.72 (1H, m), 1.64-1.57 (1H, m), 1.52-1.42 (2H, m), 1.28-1.23 (1H, m), 1.07 (9H, s), 1.06-1.03 (1H, m), 0.90 (3H, d, *J* = 6.8 Hz), 0.85 (3H, d, *J* = 6.5 Hz). ¹³C-NMR (150 MHz, CDCl₃) δ : 202.9, 135.5 (4C), 133.9 (2C), 129.4 (2C), 127.5 (4C), 69.3, 41.6, 40.3, 33.0, 29.5 (2C), 26.8 (3C), 19.2, 19.0, 16.5. IR (KBr): 2958, 1727, 1428, 1111 cm⁻¹. MS (ESI-TOF) *m/z*: 419 [M+Na]⁺. HRMS (ESI-TOF) *m/z*: 419.2382 calcd for C₂₅H₃₆O₂SiNa; Found: 419.2368.

(((2*R*,4*S*)-6-(1,3-Dithian-2-yl)-2,4-dimethylhexyl)oxy)(*tert*-butyl)diphenylsilane (12**)**

1,3-Propanedithiol (76 μ L, 0.74 mmol, 1.3 equiv.) and iodine (14.5 mg, 0.06 mmol, 0.10 equiv.) were added to a solution of **11** (226 mg, 0.57 mmol) in CHCl₃ (10 mL), and

the whole mixture was stirred for 1.3 h at rt. $\text{Na}_2\text{S}_2\text{O}_3$ / NaHCO_3 aq. was added to the mixture, and the whole mixture was extracted with CHCl_3 . Removal of the solvent from the CHCl_3 extract under reduced pressure gave a crude product, which was purified by SiO_2 column (Hexane/ AcOEt = 12:1) to give **12** (249 mg, 90%) as a colorless oil.

$[\alpha]_D^{26} +6.8$ (c 1.02, CHCl_3). $^1\text{H-NMR}$ (600 MHz, CDCl_3) δ : 7.69 (4H, d, J = 6.8 Hz), 7.45-7.38 (6H, m), 4.02 (1H, t, J = 6.9 Hz), 3.50 (1H, dd, J = 9.7, 5.8 Hz), 3.45 (1H, dd, J = 9.7, 6.5 Hz), 2.91-2.81 (4H, m), 2.13-2.10 (1H, m), 1.90-1.83 (1H, m), 1.80-1.69 (3H, m), 1.52-1.47 (2H, m), 1.37-1.32 (1H, m), 1.28-1.22 (1H, m), 1.09 (9H, s), 1.07-1.03 (1H, m), 0.91 (3H, d, J = 6.8 Hz), 0.85 (3H, d, J = 6.4 Hz). $^{13}\text{C-NMR}$ (150 MHz, CDCl_3) δ : 135.6 (4C), 133.9 (2C), 129.4 (2C), 127.5 (4C), 69.4, 48.0, 40.4, 34.6, 33.1, 33.0, 30.5, 30.4, 29.8, 26.8 (3C), 26.0, 19.30, 19.26, 16.7. IR (KBr): 2929, 1426, 1108 cm^{-1} . MS (ESI-TOF) m/z : 509 $[\text{M}+\text{Na}]^+$. HRMS (ESI-TOF) m/z : 509.2344 calcd for $\text{C}_{28}\text{H}_{42}\text{OSiS}_2\text{Na}$; Found: 509.2339.

***tert*-butyl**

(3-(2-((3*S*,5*R*)-6-Hydroxy-3,5-dimethylhexyl)-1,3-dithian-2-yl)propyl)(methyl)carbamate (13**)**

n-BuLi (1.59 M in *n*-hexane, 770 μL , 0.77 mmol, 1.5 equiv.) was added to a solution of **12** (249 mg, 0.51 mmol) in anhydrous THF (10 mL), and the whole mixture was stirred for 15 min. A solution of **21** (557 mg, 1.4 mmol, 2.7 equiv) in anhydrous THF (5 mL) was added dropwise to the mixture via cannula over 5 min at rt, and the whole mixture was stirred for 0.5 h at rt. Sat. NH_4Cl aq. was added to the mixture, and the

whole mixture was extracted with AcOEt, and the AcOEt extract was washed with NH₄Cl aq. and brine. After removal of the solvent from AcOEt extract under reduced pressure, the residue was dissolved to THF (10 mL). TBAF solution (1 M in THF, 3.0 mL) was added to the solution at rt, and the whole mixture was stirred for 8 h at rt. Sat. NH₄Cl aq. was added to the mixture, and the whole mixture was extracted with AcOEt, and the AcOEt extract was washed with NH₄Cl aq. and brine. Removal of the solvent from the AcOEt extract under reduced pressure gave a crude product, which was purified by SiO₂ column (Hexane/AcOEt = 3:1 to 1:1) to give **13** (131 mg, 61%) as a colorless oil.

$[\alpha]_D^{26} +7.6$ (*c* 0.41, CHCl₃). ¹H-NMR (600 MHz, CDCl₃) δ : 3.47 (1H, dd, *J* = 10.3, 5.9 Hz), 3.41-3.34 (1H, m), 3.28-3.17 (2H, m), 2.89 (3H, s), 2.79 (4H, d-like, *J* = 5.6 Hz), 1.95-1.90 (2H, m), 1.89-1.75 (4H, m), 1.74-1.65 (2H, m), 1.65-1.60 (2H, m), 1.53-1.45 (1H, m), 1.45 (9H, s), 1.45-1.38 (1H, m), 1.30-1.22 (1H, m), 1.20-1.14 (1H, m), 1.12-1.07 (1H, m), 0.88 (3H, d, *J* = 6.5 Hz), 0.87 (3H, d, *J* = 5.8 Hz). ¹³C-NMR (150 MHz, CDCl₃) δ : 155.8, 79.3, 68.8, 53.0, 48.5, 40.6, 35.7, 34.7, 34.2, 33.2, 31.6, 30.2, 28.5 (3C), 25.99, 25.98, 25.5, 22.7, 19.5, 16.5. IR (KBr): 3467, 2928, 1693, 1365, 1151 cm⁻¹. MS (ESI-TOF) *m/z*: 442 [M+Na]⁺. HRMS (ESI-TOF) *m/z*: 442.2426 calcd for C₂₁H₄₁NO₃S₂Na; Found: 442.2416.

tert-Butyl

(3-(2-((3*S*,5*R*)-3,5-dimethyl-6-oxohexyl)-1,3-dithian-2-yl)propyl)(methyl)carbamate

(**14**)

MS4A (130 mg) and NMO (51.1 mg, 0.44 mmol, 1.5 equiv.) were added to a solution of **13** (118 mg, 0.29 mmol) in CH₂Cl₂ (5 mL), and the whole mixture was stirred for 15 min at rt. Then, TPAP (5.1 mg, 0.015 mmol, 0.05 equiv.) was added to the mixture, and the solution was stirred for 1 h at rt. Na₂S₂O₃ / NaHCO₃ aq. and sat. CuSO₄ aq. were added to the mixture, and the whole mixture was extracted with CH₂Cl₂. Removal of the solvent from the CH₂Cl₂ extract under reduced pressure gave a crude product, which was purified by SiO₂ column (Hexane/AcOEt = 3:1) to give **14** (93 mg, 79%) as a colorless oil.

$[\alpha]_D^{27}$ -4.1 (*c* 0.39, CHCl₃). ¹H-NMR (600 MHz, CDCl₃) δ : 9.60 (1H, d, *J* = 1.8 Hz), 3.23 (2H, br), 2.85 (3H, br s), 2.79 (4H, br), 2.43 (1H, q-like, *J* = 6.5 Hz), 1.95-1.90 (2H, m), 1.89-1.78 (4H, m), 1.67-1.61 (2H, m), 1.57-1.53 (1H, m), 1.52-1.45 (2H, m), 1.45 (9H, s), 1.31-1.26 (2H, m), 1.07 (3H, d, *J* = 6.7 Hz), 0.91 (3H, d, *J* = 6.2 Hz). ¹³C-NMR (150 MHz, CDCl₃) δ : 205.2, 155.8, 79.3, 52.9, 48.7, 48.0, 44.2, 37.4, 35.8, 34.9, 34.1, 31.2, 30.5, 28.5 (3C), 26.0 (2C), 25.4, 22.8, 19.3, 13.4. IR (KBr): 2931, 1723, 1693, 1394, 1148 cm⁻¹. MS (ESI-TOF) *m/z*: 440 [M+Na]⁺. HRMS (ESI-TOF) *m/z*: 440.2269 calcd for C₂₁H₃₉NO₃S₂Na; Found: 440.2252.

Ethyl

(4*R*,6*S*,*E*)-8-(2-(3-((*tert*-Butoxycarbonyl)(methyl)amino)propyl)-1,3-dithian-2-yl)-2,4,6-trimethyloct-2-enoate (**15**)

(Carbetoxyethylidene)triphenylphosphorane (302 mg, 0.84 mmol, 4.0 equiv.) was added to the solution of **14** (87 mg, 0.21 mmol) in toluene (8 mL), and whole mixture

1
2
3
4
5
6 stirred for 44 h at 100 °C. Sat. NH₄Cl aq. was added to the mixture, and the whole
7
8 mixture was extracted with AcOEt, and the AcOEt extract was washed with NH₄Cl aq.
9
10 and brine. Removal of the solvent from the AcOEt extract under reduced pressure gave
11
12 a crude product, which was purified by SiO₂ column (Hexane/AcOEt = 10:1 to 1:1) to
13
14 give **15** (110 mg, quant.) as a colorless oil.
15
16

17
18 $[\alpha]_D^{27} -20.3$ (*c* 0.89, CHCl₃). ¹H-NMR (600 MHz, CDCl₃) δ : 6.52 (1H, d, *J* = 9.1 Hz),
19
20 4.17 (2H, q, *J* = 7.2 Hz), 3.23 (2H, br), 2.88-2.75 (7H, br), 2.63-2.58 (1H, m), 1.95-1.90
21
22 (2H, br), 1.87-1.70 (2H, m), 1.84 (3H, d, *J* = 1.1 Hz), 1.67-1.61 (2H, m), 1.57-1.53 (1H,
23
24 m), 1.52-1.45 (2H, m), 1.45 (9H, s), 1.41-1.15 (5H, m), 1.29 (3H, t, *J* = 7.2 Hz), 0.96
25
26 (3H, d, *J* = 6.4 Hz), 0.88 (3H, d, *J* = 6.4 Hz). ¹³C-NMR (150 MHz, CDCl₃) δ : 168.5,
27
28 155.8, 148.1, 126.0, 79.3, 60.4, 53.0, 48.8, 47.9, 44.1, 35.6, 34.9, 34.7, 34.1, 30.7 (2C),
29
30 30.5, 28.5 (3C), 25.97, 25.95, 25.4, 22.8, 22.5, 20.1, 19.9, 14.3, 12.5. IR (KBr): 2927,
31
32 1697, 1365, 1149 cm⁻¹. MS (ESI-TOF) *m/z*: 524 [M+Na]⁺. HRMS (ESI-TOF) *m/z*:
33
34 524.2844 calcd for C₂₆H₄₇NO₄S₂Na; Found: 524.2848.
35
36
37
38
39
40
41

42 **(4*R*,6*S*,*E*)-8-(2-(3-((*tert*-Butoxycarbonyl)(methyl)amino)propyl)-1,3-dithian-2-yl)-2,**
43
44 **4,6-trimethyloct-2-enoic acid (16)**
45

46
47 LiOH (48 mg, 2.0 mmol, 10 equiv.) was added to a solution of **15** (100 mg, 0.2
48
49 mmol) in THF / MeOH / H₂O (1:1:1, 12 mL), and the whole mixture was stirred for 24
50
51 h at rt. 5% HCl was added to the mixture, and the whole mixture was extracted with
52
53 AcOEt. Removal of the solvent from the AcOEt extract under reduced pressure gave a
54
55 crude product, which was purified by SiO₂ column (Hexane/AcOEt = 1:1) to give **16**
56
57
58
59
60

(72.6 mg, 77%) as a colorless oil.

$^1\text{H-NMR}$ (600 MHz, CDCl_3) δ : 6.67 (1H, d, $J = 8.9$ Hz), 3.23 (2H, br), 2.88-2.75 (7H, br), 2.68-2.60 (1H, m), 1.95-1.90 (2H, br), 1.87-1.70 (3H, m), 1.86 (3H, s), 1.67-1.61 (2H, m), 1.52-1.45 (1H, m), 1.46 (9H, s), 1.41-1.15 (5H, m), 0.99 (3H, d, $J = 6.7$ Hz), 0.89 (3H, d, $J = 6.1$ Hz). IR (KBr): 3200 (br), 2962, 1696, 1261, 1030 cm^{-1} . MS (ESI-TOF) m/z : 496 $[\text{M}+\text{Na}]^+$. HRMS (ESI-TOF) m/z : 496.2531 calcd for $\text{C}_{24}\text{H}_{43}\text{NO}_4\text{S}_2\text{Na}$; Found: 496.2552.

tert-Butyl

methyl(3-(2-((3*S*,5*R*,*E*)-3,5,7-trimethyl-8-(methyl(thiazol-2-ylmethyl)amino)-8-oxooct-6-en-1-yl)-1,3-dithian-2-yl)propyl)carbamate (17)

HOBt (35.8 mg, 0.27 mmol, 1.4 equiv.), *N*-methyl-1-(thiazol-2-yl)methanamine (36.4 mg, 0.28 mmol, 1.5 equiv.), Et_3N (148 μL , 1.06 mmol, 4.0 equiv.) and EDCI·HCl (50.8 mg, 0.27 mmol, 1.4 equiv.) were added to a solution of **16** (72.6 mg, 0.19 mmol) in CH_2Cl_2 (15 mL), and the whole mixture was stirred for 48 h at rt. Sat. NH_4Cl aq. was added to the mixture, and the whole mixture was extracted with AcOEt, and the AcOEt extract was washed with Sat. NH_4Cl aq., NaHCO_3 aq., and brine. Removal of the solvent from the AcOEt extract under reduced pressure gave a crude product, which was purified by SiO_2 column (Hexane/AcOEt = 1:2) to give **17** (86.1 mg, 92%) as a colorless oil.

$[\alpha]_{\text{D}}^{27} -24.7$ (c 0.43, CHCl_3). Mixture of rotamers. $^1\text{H-NMR}$ (600 MHz, CDCl_3) δ : 7.66 (1H, br s), 7.28 (1H, d, $J = 2.6$ Hz), 5.33 (1H, br), 4.82 (2H, s), 3.16 (2H, br), 2.98 (3H,

br s), 2.80-2.76 (7H, br), 2.55-2.48 (1H, m), 1.95-1.50 (8H, m), 1.83 (3H, d, $J = 1.1$ Hz), 1.48-1.00 (5H, m), 1.39 (9H, s), 0.88 (3H, br), 0.81 (3H, br). ^{13}C -NMR (150 MHz, CDCl_3) δ : 173.4, 166.6, 155.6, 141.9, 138.2, 128.8, 119.9, 119.5, 79.1, 60.2, 52.9, 52.8, 48.6, 48.2, 47.7, 44.2, 36.8, 35.5, 34.7, 34.5, 33.9, 30.6, 30.3, 30.2, 29.6, 28.3 (3C), 25.8 (2C?), 25.2, 22.6, 22.3, 20.0, 19.9, 14.1. IR (KBr): 2926, 1692, 1632, 1393, 1147 cm^{-1} . MS (ESI-TOF) m/z : 606 $[\text{M}+\text{Na}]^+$. HRMS (ESI-TOF) m/z : 606.2834 calcd for $\text{C}_{29}\text{H}_{49}\text{N}_3\text{O}_3\text{S}_3\text{Na}$; Found: 606.2857.

***tert*-Butyl**

methyl((7*S*,9*R*,*E*)-7,9,11-trimethyl-12-(methyl(thiazol-2-ylmethyl)amino)-4,12-dioxododec-10-en-1-yl)carbamate (18**)**

Iodine (142 mg, 0.56 mmol, 4 equiv.) was added to a solution of **17** (81.4 mg, 0.1400 mmol) in a mixture of CH_3CN (6 mL) and sat. NaHCO_3 aq. (3 mL) at 0 °C, and the whole mixture was stirred for 1.3 h at 0 °C. $\text{Na}_2\text{S}_2\text{O}_3$ / NaHCO_3 aq. was added to the mixture, and the whole mixture was extracted with AcOEt, and the AcOEt extract was washed with $\text{Na}_2\text{S}_2\text{O}_3$ / NaHCO_3 aq. and brine. Removal of the solvent from the AcOEt extract under reduced pressure gave a crude product, which was purified by SiO_2 column (Hexane/AcOEt = 1:3 to 0:1) to give **18** (32.6 mg, 47%) as a colorless oil.

$[\alpha]_{\text{D}}^{27} -16.2$ (c 1.11, CHCl_3). Mixture of rotamers. ^1H -NMR (600 MHz, CDCl_3) δ : 7.57 (1H, br s), 7.21 (1H, d, $J = 3.0$ Hz), 5.26 (1H, br), 4.73 (2H, s), 3.06 (2H, t-like), 2.89 (3H, br s), 2.67 (3H, br s), 2.43-2.38 (1H, m), 2.30-2.15 (2H, m), 2.25 (2H, t, $J = 7.0$ Hz), 1.73 (3H, br s), 1.62 (2H, quint, $J = 7.0$ Hz), 1.52-1.44 (1H, br), 1.30 (9H, s),

1.20-0.90 (3H, m), 0.79 (3H, br), 0.69 (3H, br). ^{13}C -NMR (150 MHz, CDCl_3) δ : 210.0, 209.7, 173.2, 166.4, 155.5, 155.3, 141.8, 137.9, 128.6, 119.7, 78.9, 78.8, 52.3, 48.0, 47.7, 47.2, 43.9, 39.9, 39.1, 39.0, 36.6, 33.6, 29.9, 29.7, 29.3, 28.0, 21.5, 21.1, 19.7, 19.3, 13.9. IR (KBr): 2926, 1692, 1632, 1393, 1169 cm^{-1} . MS (ESI-TOF) m/z : 516 $[\text{M}+\text{Na}]^+$. HRMS (ESI-TOF) m/z : 516.2872 calcd for $\text{C}_{26}\text{H}_{43}\text{N}_3\text{O}_4\text{SNa}$; Found: 516.2887.

tert-Butyl

((*4EZ,7S,9R,10E*)-4-(chloromethylene)-7,9,11-trimethyl-12-(methyl(thiazol-2-ylmethyl)amino)-12-oxododec-10-en-1-yl)(methyl)carbamate (19**)**

LHMDS solution (1.0 M in THF, 320 μL , 0.32 mmol, 4.8 equiv.) was added to a solution of (chloromethyl)triphenylphosphonium chloride (114 mg, 0.33 mmol, 5.0 equiv.) in anhydrous THF (3 mL), and the whole mixture was stirred for 10 min. A solution of **18** (32.6 mg, 0.066 mmol) in anhydrous THF (1 mL) was added dropwise to the mixture via cannula over 5 min at rt, and the whole mixture was stirred for 1 h at rt. Sat. NH_4Cl aq. was added to the mixture, and the whole mixture was extracted with AcOEt, and the AcOEt extract was washed with NH_4Cl aq. and brine. Removal of the solvent from AcOEt extract under reduced pressure gave a crude product, which was purified by SiO_2 column (Hexane/AcOEt = 1:2) to give **19** (34.5 mg, 99%) as a colorless oil.

E/Z mixture (*E/Z* = 3:2). ^1H -NMR (600 MHz, CDCl_3) δ : 7.72 (1H, br s), 7.32 (1H, d, J = 3.0 Hz), 5.77 (1H, br s), 5.41 (1H, br), 4.87 (2H, s), 3.18 (2H, br), 3.03 (3H, br s),

2.83 (3H, br), 2.60-2.50 (1H, m), 2.20-2.05 (2H, m), 2.04-1.92 (2H, m), 1.87 (0.6x3H, s), 1.86 (0.4x3H, s), 1.73 (1H, br), 1.64-1.56 (2H, m), 1.443 (0.4x9H, s), 1.440 (0.6x9H, s), 1.44-1.10 (4H, m), 0.93 (3H, br), 0.88 (0.6x3H, br), 0.85 (0.4x3H, br). ¹³C-NMR (150 MHz, CDCl₃) δ: 173.7, 166.9, 155.8, 155.7, 142.2, 138.4, 128.86, 128.82, 120.1, 112.2, 79.3, 79.2, 48.8, 48.5, 48.2, 48.1, 44.18, 44.16, 37.0, 34.9, 34.2, 33.9, 32.3, 32.0, 30.6, 30.2, 29.84, 29.80, 28.5, 27.6, 27.5, 25.8, 25.6, 25.5, 25.0, 20.0, 19.9, 19.8, 19.7, 14.3. IR (KBr): 2926, 1693, 1632, 1393, 1168 cm⁻¹. MS (ESI-TOF) *m/z*: 548/550 (3:1) [M+Na]⁺. HRMS (ESI-TOF) *m/z*: 548.2690 calcd for C₂₇H₄₄N₃O₃S³⁵ClNa; Found: 548.2692.

Biakamide A (1) and B (2)

TFA (33 μL, 0.45mmol, 10 equiv.) was added to a solution of **19** (23.5 mg, 0.045 mmol) in CH₂Cl₂ (1 mL), and the whole mixture was stirred for 7 h. Sat. NaHCO₃ aq. was added to the mixture, and the whole mixture was extracted with AcOEt. Removal of the solvent from AcOEt extract under reduced pressure gave an amine **20**, which was used in the next reaction without further purification.

38% aliquot of the above amine was dissolved to CH₂Cl₂ (3 mL). HOBt (3.9 mg, 0.047 mmol, 1.4 equiv.), (S)-3-hydroxybutyric acid (6.0 mg, 0.05 mmol, 1.5 equiv.), Et₃N (24 μL, 0.17 mmol, 6.0 equiv.) and EDCI·HCl (5.6 mg, 0.029 mmol, 1.4 equiv.) were added to the solution, and the whole mixture was stirred for 15 h at rt. Sat. NH₄Cl aq. was added to the mixture, and the whole mixture was extracted with AcOEt, and the AcOEt extract was washed with Sat. NH₄Cl aq., NaHCO₃ aq., and brine. Removal of

the solvent from AcOEt extract under reduced pressure gave a crude product, which was purified by SiO₂ column (AcOEt/MeOH = 5:1) to give a mixture of **1** and **2** (7.6 mg, 74%, two steps) as a white powder. HPLC separation (Cosmosil 5C₁₈-MS-II, 10 mm i.d. × 250 mm, MeOH/H₂O = 60:40, flow rate = 3.5 mL/min) yielded pure **1** and **2**.

(4*R*,6*S*)-biakamide A (**1**): $[\alpha]_D^{28} +1.2$ (*c* 0.57, CHCl₃). Mixture of rotamers. ¹H-NMR (600 MHz, CDCl₃) δ : 7.72 (1H, br s), 7.32 (1H, br s), 5.79 (0.4x1H, s), 5.78 (0.6x1H, s), 5.41 (1H, br), 4.87 (2H, s), 4.40 (0.4x1H, s), 4.38 (0.6x1H, s), 4.20-4.16 (1H, m), 3.36-3.30 (0.6x2H, t-like), 3.27-3.18 (0.4x2H, m), 3.03 (3H, br s), 2.94 (0.6x3H, s), 2.91 (0.4x3H, s), 2.55 (1H, br), 2.45 (1H, dd, *J* = 16.5, 2.1 Hz), 2.27 (1H, dd, *J* = 16.5, 9.6 Hz), 2.23-2.15 (1H, m), 2.15-2.08 (1H, m), 2.07-2.05 (2H, m), 1.87 (3H, s), 1.80 (1H, br), 1.70-1.59 (2H, m), 1.45-1.35 (2H, br), 1.33-1.08 (3H, m), 1.21 (3H, d, *J* = 6.6 Hz), 0.94 (3H, br), 0.88 (3H, br). ¹³C-NMR (150 MHz, CDCl₃) δ : 173.6, 172.5, 172.4, 166.9, 142.2, 142.0, 141.4, 138.0, 128.87, 128.82, 120.0, 112.9, 112.4, 64.2, 64.1, 52.8, 49.0, 48.3, 47.2, 44.1, 41.1, 40.5, 37.0, 35.2, 33.9, 33.8, 33.0, 32.1, 31.7, 30.5, 29.78, 29.75, 29.6, 27.54, 27.50, 26.0, 25.1, 22.2, 22.1, 20.04, 20.01, 19.3, 14.1. IR (KBr): 3434, 2925, 1631, 1394 cm⁻¹. MS (ESI-TOF) *m/z*: 534/536 (3:1) [M+Na]⁺. HRMS (ESI-TOF) *m/z*: 534.2533 calcd for C₂₆H₄₂N₃O₃S³⁵ClNa; Found: 534.2513.

(4*R*,6*S*)-biakamide B (**2**): $[\alpha]_D^{26} +4.1$ (*c* 0.42, CHCl₃). Mixture of rotamers. ¹H-NMR (600 MHz, CDCl₃) δ : 7.72 (1H, br s), 7.33 (1H, d, *J* = 2.4 Hz), 5.84 (0.4x1H, s), 5.78 (0.6x1H, s), 5.41 (1H, br), 4.87 (2H, s), 4.45 (1H, br), 4.22-4.15 (1H, m), 3.38 (0.6x2H, t-like), 3.30-3.22 (0.4x2H, m), 3.03 (3H, br s), 2.96 (0.6x3H, s), 2.93 (0.4x3H, s), 2.52 (1H, br), 2.46 (1H, ddd, *J* = 16.2, 9.0, 1.8 Hz), 2.29 (1H, ddd, *J* = 16.2, 9.6, 6.6 Hz),

2.23-2.14 (2H, m), 2.13-2.07 (1H, br), 2.02-1.94 (1H, br), 1.86 (3H, s), 1.71-1.60 (2H, m), 1.44-1.35 (1H, br), 1.25-1.08 (3H, m), 1.22 (3H, d, $J = 6.6$ Hz), 0.94 (3H, br), 0.85 (3H, br). ^{13}C -NMR (150 MHz, CDCl_3) δ : 173.5, 172.5, 172.4, 166.8, 142.0 (br), 142.0, 141.4, 138.4, 128.84, 128.77, 120.0, 113.1, 112.5, 64.3, 64.1, 52.6, 49.3, 48.4, 47.2, 44.1, 41.1, 40.4, 36.9, 35.1, 34.9, 33.1, 32.5, 32.2, 30.2, 30.1, 29.74, 29.71, 27.4, 27.3, 25.6, 24.6, 22.2, 22.1, 19.92, 19.89, 19.6, 14.2. IR (KBr): 3435, 2962, 1628, 1398, 1261 cm^{-1} . MS (ESI-TOF) m/z : 534/536 (3:1) $[\text{M}+\text{Na}]^+$. HRMS (ESI-TOF) m/z : 534.2533 calcd for $\text{C}_{26}\text{H}_{42}\text{N}_3\text{O}_3\text{S}^{35}\text{ClNa}$; Found: 534.2525.

Biakamide C (3) and D (4)

62% aliquot of the above amine **20** was dissolved to CH_2Cl_2 (3 mL). HOBt (6.4 mg, 0.047 mmol, 1.4 equiv.), (*E*)-3-methoxybut-2-enoic acid (5.6 mg, 0.050 mmol, 1.5 equiv.), Et_3N (39 μL , 0.28 mmol, 6.0 equiv.) and $\text{EDCI} \cdot \text{HCl}$ (9.0 mg, 0.047 mmol, 1.4 equiv.) were added to the solution, and whole mixture stirred for 25 h at rt. Sat. NH_4Cl aq. was added to the mixture, and the whole mixture was extracted with AcOEt , and the AcOEt extract was washed with Sat. NH_4Cl aq., NaHCO_3 aq., and brine. Removal of the solvent from AcOEt extract under reduced pressure gave a crude product, which was purified by SiO_2 column ($\text{AcOEt}/\text{MeOH} = 50:1$) to give a mixture of **3** and **4** (13.8 mg, 78%) as a white powder. HPLC separation (Cosmosil $5\text{C}_{18}\text{-MS-II}$, 10 mm i.d. \times 250 mm, $\text{MeOH}/\text{H}_2\text{O} = 70:30$, flow rate = 4.0 mL/min) yielded pure **3** and **4**.

(4*R*,6*S*)-biakamide C (**3**): $[\alpha]_{\text{D}}^{27} -17.3$ (c 0.48, CHCl_3). Mixture of rotamers. ^1H -NMR (600 MHz, CDCl_3) δ : 7.72 (1H, br s), 7.33 (1H, d, $J = 3.0$ Hz), 5.78 (1H, s), 5.41 (1H,

br), 5.15 (1H, s), 4.87 (2H, s), 3.61 (0.6x3H, s), 3.59 (0.4x3H, s), 3.40-3.34 (0.6x2H, br), 3.32-3.25 (0.4x2H, br), 3.03 (3H, br s), 3.00 (0.6x3H, s), 2.94 (0.4x3H, s), 2.59-2.51 (1H, br), 2.19 (3H, s), 2.20-1.08 (2H, m), 2.05 (2H, t, $J = 7.5$ Hz), 1.87 (3H, s), 1.76-1.62 (4H, m), 1.45-1.36 (2H, m), 1.30-1.25 (1H, m), 1.20-1.10 (2H, m), 0.94 (3H, d, $J = 3.6$ Hz), 0.88 (3H, br). ^{13}C -NMR (150 MHz, CDCl_3) δ : 173.7, 168.6, 168.2, 168.0, 166.9, 142.3, 142.2, 141.7, 138.4, 128.8, 120.0, 112.7, 112.2, 91.2, 90.9, 54.8, 52.6, 49.7, 48.3, 47.2, 44.1, 37.1, 36.0, 33.9, 33.4, 32.2, 31.6, 30.5, 29.8, 29.7, 27.6, 26.0, 25.5, 20.0, 19.8, 18.7, 14.2. IR (KBr): 2924, 1639, 1453, 1379, 1239 cm^{-1} . MS (ESI-TOF) m/z : 546/548 (3:1) $[\text{M}+\text{Na}]^+$. HRMS (ESI-TOF) m/z : 546.2533 calcd for $\text{C}_{27}\text{H}_{42}\text{N}_3\text{O}_3\text{S}^{35}\text{ClNa}$; Found: 546.2512.

(4*R*,6*S*)-biakamide D (**4**): $[\alpha]_{\text{D}}^{29} -11.4$ (c 0.35, CHCl_3). Mixture of rotamers. ^1H -NMR (600 MHz, CDCl_3) δ : 7.72 (1H, br s), 7.32 (1H, d, $J = 3.0$ Hz), 5.81 (0.5x1H, br s), 5.77 (0.5x1H, br s), 5.40 (1H, br), 5.17 (1H, s), 4.87 (2H, s), 3.60 (3H, s), 3.42 (0.5x2H, t-like), 3.33 (0.5x2H, t-like), 3.02 (3H+0.5x3H, br s), 2.95 (0.5x 3H, br s), 2.52 (1H, br), 2.19 (3H, s), 2.20-2.16 (2H, m), 2.14-2.06 (1H, m), 2.02-1.96 (1H, m), 1.86 (3H, s), 1.77-1.60 (4H, m), 1.42-1.05 (4H, m), 0.93 (3H, br), 0.85 (3H, br). ^{13}C -NMR (150 MHz, CDCl_3) δ : 173.6, 168.4, 168.1, 168.0, 166.8, 142.4, 142.1, 141.8, 138.4, 128.8, 120.0, 112.8, 112.2, 91.3, 91.0, 54.84, 54.78, 52.8, 50.2, 48.4, 47.3, 44.1, 36.9, 35.9, 34.9, 33.5, 32.32, 32.25, 30.1, 29.8, 27.6, 27.5, 26.0, 24.9, 19.9, 19.6, 18.7, 14.2. IR (KBr): 2962, 1645, 1261, 1102 cm^{-1} . MS (ESI-TOF) m/z : 546/548 (3:1) $[\text{M}+\text{Na}]^+$. HRMS (ESI-TOF) m/z : 546.2533 calcd for $\text{C}_{27}\text{H}_{42}\text{N}_3\text{O}_3\text{S}^{35}\text{ClNa}$; Found: 546.2513.

Synthesis of (4*R*,6*R*)-isomer of biakamides

Using the same procedures as those for the synthesis of (4*R*,6*S*)-isomers, (4*R*,6*R*)-isomers of biakamides were obtained starting from (2*S*,4*R*)-5-((*tert*-Butyldiphenylsilyl)oxy)-2,4-dimethylpentan-1-ol (**6'**).⁴²

Methyl (4*S*,6*R*,*E*)-7-((*tert*-butyldiphenylsilyl)oxy)-4,6-dimethylhept-2-enoate (**7'**)

Yield: 86%. $[\alpha]_D^{27} +18.7$ (*c* 3.19, CHCl₃). ¹H-NMR (600 MHz, CDCl₃) δ : 7.68 (4H, d, *J* = 7.7 Hz), 7.45-7.38 (6H, m), 6.84 (1H, dd, *J* = 15.8, 8.4 Hz), 5.81 (1H, d, *J* = 15.8 Hz), 3.75 (3H, s), 3.50-3.43 (2H, m), 2.42 (1H, quint, *J* = 6.5 Hz), 1.70-1.65 (1H, m), 1.59-1.53 (1H, m), 1.16-1.11 (1H, m), 1.08 (9H, s), 1.04 (3H, d, *J* = 6.4 Hz), 0.92 (3H, d, *J* = 6.4 Hz). ¹³C-NMR (150 MHz, CDCl₃) δ : 167.3, 154.8, 135.644 (2C), 135.637 (2C), 133.90, 133.86, 129.6 (2C), 127.6 (4C), 119.4, 69.0, 51.4, 39.8, 34.2, 33.4, 26.9 (3C), 20.5, 19.3, 16.7. IR (KBr): 2958, 1725, 1626, 1273, 1112 cm⁻¹. MS (ESI-TOF) *m/z*: 447 [M+Na]⁺. HRMS (ESI-TOF) *m/z*: 447.2331 calcd for C₂₆H₃₆O₃SiNa; Found: 447.2323.

Methyl (4*R*,6*R*)-7-((*tert*-butyldiphenylsilyl)oxy)-4,6-dimethylheptanoate (**8'**)

Yield: 80%. $[\alpha]_D^{27} +6.4$ (*c* 1.59, CHCl₃). ¹H-NMR (600 MHz, CDCl₃) δ : 7.67 (4H, d, *J* = 6.8 Hz), 7.44-7.37 (6H, m), 3.66 (3H, s), 3.50 (1H, dd, *J* = 9.7, 5.4 Hz), 3.42 (1H, dd, *J* = 9.7, 6.5 Hz), 2.33 (1H, ddd, *J* = 15.5, 10.0, 5.6 Hz), 2.25 (1H, ddd, *J* = 15.5, 9.8, 6.2 Hz), 1.78-1.72 (1H, m), 1.71-1.64 (1H, m), 1.51-1.44 (1H, m), 1.40-1.32 (2H, m), 1.06 (9H, s), 0.96-0.91 (1H, m), 0.93 (3H, d, *J* = 6.7 Hz), 0.84 (3H, d, *J* = 6.7 Hz). ¹³C-NMR (150 MHz, CDCl₃) δ : 174.6, 135.64 (2C), 135.63 (2C), 134.0 (2C), 129.5 (2C), 127.6

(4C), 68.8, 51.5, 40.7, 33.0, 31.64, 31.57, 29.7, 26.9 (3C), 19.9, 19.3, 17.6. IR (KBr): 2955, 1740, 1428, 1171, 1112 cm^{-1} . MS (ESI-TOF) m/z : 449 $[\text{M}+\text{Na}]^+$. HRMS (ESI-TOF) m/z : 449.2488 calcd for $\text{C}_{26}\text{H}_{38}\text{O}_3\text{SiNa}$; Found: 449.2478.

(4*R*,6*R*)-7-((*tert*-Butyldiphenylsilyl)oxy)-4,6-dimethylheptanoic acid (9')

Yield: 80%. $[\alpha]_{\text{D}}^{26} +6.8$ (c 1.06, CHCl_3). ^1H -NMR (600 MHz, CDCl_3) δ : 7.67 (4H, d, J = 6.7 Hz), 7.44-7.36 (6H, m), 3.49 (1H, dd, J = 9.7, 5.3 Hz), 3.42 (1H, dd, J = 9.7, 6.4 Hz), 2.37 (1H, ddd, J = 15.9, 10.0, 5.6 Hz), 2.29 (1H, ddd, J = 15.9, 9.7, 6.5 Hz), 1.77-1.65 (2H, m), 1.53-1.47 (1H, m), 1.41-1.33 (2H, m), 1.06 (9H, s), 0.96-0.92 (1H, m), 0.93 (3H, d, J = 6.8 Hz), 0.85 (3H, d, J = 6.5 Hz). ^{13}C -NMR (150 MHz, CDCl_3) δ : 180.3, 135.64 (2C), 135.63 (2C), 134.0 (2C), 129.5 (2C), 127.6 (4C), 68.8, 40.7, 33.0, 31.6, 31.3, 29.6, 26.9 (3C), 19.8, 19.3, 17.6. IR (KBr): 3100 (br), 2957, 1709, 1427, 1112 cm^{-1} . MS (ESI-TOF) m/z : 435 $[\text{M}+\text{Na}]^+$. HRMS (ESI-TOF) m/z : 435.2331 calcd for $\text{C}_{25}\text{H}_{36}\text{O}_3\text{SiNa}$; Found: 435.2317.

(4*R*,6*R*)-7-((*tert*-Butyldiphenylsilyl)oxy)-4,6-dimethylheptanal (11')

Yield: 66% (2 steps). $[\alpha]_{\text{D}}^{26} +6.3$ (c 2.03, CHCl_3). ^1H -NMR (600 MHz, CDCl_3) δ : 9.76 (1H, s), 7.68 (4H, d, J = 6.7 Hz), 7.44-7.38 (6H, m), 3.50 (1H, dd, J = 9.9, 5.4 Hz), 3.44 (1H, dd, J = 9.9, 6.3 Hz), 2.45-2.33 (2H, m), 1.76-1.71 (1H, m), 1.68-1.63 (1H, m), 1.53-1.47 (1H, m), 1.42-1.33 (2H, m), 1.07 (9H, s), 0.97-0.92 (1H, m), 0.94 (3H, d, J = 6.7 Hz), 0.85 (3H, d, J = 6.8 Hz). ^{13}C -NMR (150 MHz, CDCl_3) δ : 202.9, 135.58 (2C), 135.56 (2C), 133.9 (2C), 129.5 (2C), 127.5 (4C), 68.7, 41.4, 40.6, 33.0, 29.6, 28.5, 26.8

(3C), 19.9, 19.3, 17.6. IR (KBr): 2957, 1726, 1471, 1427, 1111 cm^{-1} . MS (ESI-TOF) m/z : 419 $[\text{M}+\text{Na}]^+$. HRMS (ESI-TOF) m/z : 419.2382 calcd for $\text{C}_{25}\text{H}_{36}\text{O}_2\text{SiNa}$; Found: 419.2383.

**(((2*R*,4*R*)-6-(1,3-Dithian-2-yl)-2,4-dimethylhexyl)oxy)(*tert*-butyl)diphenylsilane
(12')**

Yield: 80%. $[\alpha]_{\text{D}}^{27} +7.1$ (c 1.12, CHCl_3). ^1H -NMR (600 MHz, CDCl_3) δ : 7.67 (4H, d, J = 7.6 Hz), 7.45-7.37 (6H, m), 3.99 (1H, t, J = 6.9 Hz), 3.50 (1H, dd, J = 9.9, 5.2 Hz), 3.40 (1H, dd, J = 9.9, 6.6 Hz), 2.90-2.80 (4H, m), 2.13-2.10 (1H, m), 1.90-1.82 (1H, m), 1.80-1.65 (3H, m), 1.55-1.43 (2H, m), 1.38-1.33 (1H, m), 1.28-1.22 (1H, m), 1.06 (9H, s), 0.93-0.88 (1H, m), 0.93 (3H, d, J = 6.8 Hz), 0.83 (3H, d, J = 6.7 Hz). ^{13}C -NMR (150 MHz, CDCl_3) δ : 135.6 (4C), 134.0 (2C), 129.5 (2C), 127.6 (4C), 68.8, 48.0, 40.9, 33.6, 33.0, 32.9, 30.55, 30.47, 29.9, 26.9 (3C), 26.1, 20.1, 19.3, 17.8. IR (KBr): 2930, 1470, 1427, 1111 cm^{-1} . MS (ESI-TOF) m/z : 509 $[\text{M}+\text{Na}]^+$. HRMS (ESI-TOF) m/z : 509.2344 calcd for $\text{C}_{28}\text{H}_{42}\text{OSiS}_2\text{Na}$; Found: 509.2332.

***tert*-Butyl**

(3-(2-((3*R*,5*R*)-6-Hydroxy-3,5-dimethylhexyl)-1,3-dithian-2-yl)propyl)(methyl)carbamate (13')

Yield: 69% (2 steps). $[\alpha]_{\text{D}}^{27} +6.4$ (c 1.87, CHCl_3). Mixture of rotamers. ^1H -NMR (600 MHz, CDCl_3) δ : 3.46 (1H, br), 3.35 (1H, dd, J = 10.6, 6.8 Hz), 3.20 (2H, br), 2.83 (3H,

br), 2.77 (4H, br), 1.95-1.59 (9H, m), 1.50-1.44 (1H, m), 1.43 (9H, s), 1.35-1.32 (1H, m), 1.22-1.16 (1H, m), 0.97-0.92 (1H, m), 0.90 (3H, d, $J = 6.4$ Hz), 0.89 (3H, d, $J = 6.2$ Hz). ^{13}C -NMR (150 MHz, CDCl_3) δ : 155.8, 79.3, 68.2, 53.0, 48.7, 48.1, 40.8, 40.5, 35.4, 35.2, 34.8, 34.5, 34.1, 33.3, 33.1, 30.3, 30.2, 29.9, 28.4 (3C), 25.9, 25.4, 22.8, 22.4, 20.4, 17.2. IR (KBr): 3456, 2928, 1694, 1395, 1151 cm^{-1} . MS (ESI-TOF) m/z : 442 $[\text{M}+\text{Na}]^+$. HRMS (ESI-TOF) m/z : 442.2426 calcd for $\text{C}_{21}\text{H}_{41}\text{NO}_3\text{S}_2\text{Na}$; Found: 442.2421.

***tert*-Butyl**

(3-(2-((3*R*,5*R*)-3,5-dimethyl-6-oxohexyl)-1,3-dithian-2-yl)propyl)(methyl)carbamate (14')

Yield: 84%. $[\alpha]_{\text{D}}^{27} -0.1$ (c 2.06, CHCl_3). Mixture of rotamers. ^1H -NMR (600 MHz, CDCl_3) δ : 9.56 (1H, d, $J = 2.0$ Hz), 3.20 (2H, br), 2.83 (3H, br s), 2.77 (4H, br), 2.41 (1H, q-like, $J = 6.4$ Hz), 1.95-1.70 (6H, m), 1.64-1.59 (2H, m), 1.47-1.42 (1H, m), 1.43 (9H, s), 1.25-1.20 (1H, m), 1.13 (1H, quint, $J = 7.0$ Hz), 1.07 (3H, d, $J = 7.1$ Hz), 0.90 (3H, d, $J = 6.4$ Hz). ^{13}C -NMR (150 MHz, CDCl_3) δ : 205.1, 155.7, 79.2, 52.8, 48.6, 47.8, 43.9, 37.9, 35.4, 34.9, 34.6, 34.0, 30.6, 30.5, 28.4 (3C), 25.8, 25.3, 22.7, 22.3, 19.7, 14.0. IR (KBr): 2932, 1723, 1693, 1393, 1149 cm^{-1} . MS (ESI-TOF) m/z : 440 $[\text{M}+\text{Na}]^+$. HRMS (ESI-TOF) m/z : 440.2269 calcd for $\text{C}_{21}\text{H}_{39}\text{NO}_3\text{S}_2\text{Na}$; Found: 440.2277.

Ethyl

(4*R*,6*R*,*E*)-8-(2-(3-((*tert*-Butoxycarbonyl)(methyl)amino)propyl)-1,3-dithian-2-yl)-2,4,6-trimethyloct-2-enoate (15')

Yield: 87%. $[\alpha]_D^{27} -8.0$ (c 2.45, CHCl_3). $^1\text{H-NMR}$ (600 MHz, CDCl_3) δ : 6.45 (1H, d, J = 10.3 Hz), 4.18-4.13 (2H, m), 3.20 (2H, br), 2.82 (3H, br s), 2.80-2.70 (4H, br), 2.62-2.55 (1H, m), 1.91 (2H, br s), 1.85-1.75 (3H, m), 1.81 (3H, s), 1.65-1.58 (2H, m), 1.43 (9H, s), 1.40-1.32 (2H, m), 1.31-1.12 (5H, m), 1.27 (3H, t, J = 7.0 Hz), 0.95 (3H, d, J = 6.4 Hz), 0.83 (3H, d, J = 6.4 Hz). $^{13}\text{C-NMR}$ (150 MHz, CDCl_3) δ : 168.3, 155.7, 147.7, 126.3, 79.2, 60.3, 52.9, 48.7, 47.9, 44.2, 35.6, 34.8, 34.0, 31.5, 30.9, 30.7, 28.4 (3C), 25.9, 25.4, 22.6, 20.6, 19.4, 14.2, 12.4. IR (KBr): 2930, 1698, 1392, 1263, 1150 cm^{-1} . MS (ESI-TOF) m/z : 524 $[\text{M}+\text{Na}]^+$. HRMS (ESI-TOF) m/z : 524.2844 calcd for $\text{C}_{26}\text{H}_{47}\text{NO}_4\text{S}_2\text{Na}$; Found: 524.2842.

(4*R*,6*R*,*E*)-8-(2-(3-((*tert*-Butoxycarbonyl)(methyl)amino)propyl)-1,3-dithian-2-yl)-2,4,6-trimethyloct-2-enoic acid (16')

Yield: quant. $^1\text{H-NMR}$ (600 MHz, CDCl_3) δ : 6.57 (1H, d, J = 8.9 Hz), 3.17 (2H, br), 2.80-2.72 (7H, br), 2.62-2.54 (1H, m), 1.90-1.83 (2H, br), 1.80-1.70 (4H, m), 1.79 (3H, s), 1.60-1.55 (2H, m), 1.39 (9H, s), 1.38-1.10 (5H, m), 0.93 (3H, d, J = 6.8 Hz), 0.80 (3H, d, J = 7.6 Hz). IR (KBr): 3100 (br), 2930, 1690, 1395, 1276, 1152 cm^{-1} . MS (ESI-TOF) m/z : 496 $[\text{M}+\text{Na}]^+$. HRMS (ESI-TOF) m/z : 496.2531 calcd for $\text{C}_{24}\text{H}_{43}\text{NO}_4\text{S}_2\text{Na}$; Found: 496.2531.

***tert*-Butyl**

methyl(3-(2-((3*R*,5*R*,*E*)-3,5,7-trimethyl-8-(methyl(thiazol-2-ylmethyl)amino)-8-oxooct-6-en-1-yl)-1,3-dithian-2-yl)propyl)carbamate (17')

Yield: 84%. $[\alpha]_D^{27} -6.2$ (*c* 1.57, CHCl₃). Mixture of rotamers. ¹H-NMR (600 MHz, CDCl₃) δ : 7.71 (1H, br s), 7.32 (1H, d, *J* = 2.4 Hz), 5.35 (1H, br), 4.86 (2H, s), 3.20 (2H, br), 3.02 (3H, br s), 2.85-2.70 (7H, br), 2.56 (1H, br), 1.95-1.65 (6H, m), 1.87 (3H, s), 1.63-1.58 (2H, m), 1.43 (9H, s), 1.38-1.10 (5H, m), 0.94 (3H, br), 0.86 (3H, br). ¹³C-NMR (150 MHz, CDCl₃) δ : 173.7, 166.8, 155.8, 142.3, 138.2, 129.3, 120.1, 79.3, 60.2, 53.0, 52.9, 48.7, 47.9, 44.4, 37.0, 35.6, 34.9, 34.6, 34.0, 31.5, 30.9, 29.9, 28.5 (3C), 25.9 (2C?), 25.4, 22.8, 22.5, 20.9, 19.5, 14.3. IR (KBr): 2927, 1692, 1631, 1393, 1149 cm⁻¹. MS (ESI-TOF) *m/z*: 606 [M+Na]⁺. HRMS (ESI-TOF) *m/z*: 606.2834 calcd for C₂₉H₄₉N₃O₃S₃Na; Found: 606.2855.

***tert*-Butyl**

methyl((7*R*,9*R*,*E*)-7,9,11-trimethyl-12-(methyl(thiazol-2-ylmethyl)amino)-4,12-dioxododec-10-en-1-yl)carbamate (18')

Yield: 98%. $[\alpha]_D^{26} -12.2$ (*c* 1.72, CHCl₃). Mixture of rotamers. ¹H-NMR (600 MHz, CDCl₃) δ : 7.49 (1H, br s), 7.15 (1H, br s), 5.14 (1H, br), 4.65 (2H, s), 2.98 (2H, t-like), 2.81 (3H, br s), 2.59 (3H, br s), 2.35 (1H, br), 2.20-2.10 (2H, m), 2.16 (2H, t, *J* = 7.0 Hz), 1.65 (3H, s), 1.53 (2H, quint, *J* = 7.0 Hz), 1.35-1.25 (1H, br), 1.22 (9H, s), 1.15-0.95 (3H, m), 0.90 (1H, br), 0.74 (3H, br), 0.62 (3H, br). ¹³C-NMR (150 MHz, CDCl₃) δ : 209.7, 209.4, 172.9, 166.2, 155.2, 155.1, 141.6, 137.3, 128.8, 119.6, 78.6, 78.5, 52.2, 47.8, 47.5, 46.9, 43.9, 39.8, 38.8, 37.7, 36.5, 33.4, 32.7, 30.6, 29.9, 29.3, 27.9, 21.3, 20.9, 20.3, 18.7, 13.8. IR (KBr): 2927, 1693, 1632, 1393, 1169 cm⁻¹. MS (ESI-TOF) *m/z*: 516 [M+Na]⁺. HRMS (ESI-TOF) *m/z*: 516.2872 calcd for

C₂₆H₄₃N₃O₄SNa; Found: 516.2856.

***tert*-Butyl**

((4*EZ*,7*R*,9*R*,10*E*)-4-(chloromethylene)-7,9,11-trimethyl-12-(methyl(thiazol-2-ylmethyl)amino)-12-oxododec-10-en-1-yl)(methyl)carbamate (19')

Yield: 89%. *E/Z* mixture (*E/Z* = 3:2). ¹H-NMR (600 MHz, CDCl₃) δ: 7.60 (1H, br s), 7.23 (1H, br s), 5.64 (1H, br s), 5.26 (1H, br), 4.76 (2H, s), 3.06 (2H, br), 2.92 (3H, br s), 2.71 (3H, br), 2.50-2.40 (1H, m), 2.05-1.95 (2H, m), 1.89 (2H, t, *J* = 7.4 Hz), 1.77 (3H, s), 1.50-1.42 (2H, m), 1.33 (9H, s), 1.25-0.95 (5H, m), 0.85 (3H, br), 0.78 (0.6x3H, br), 0.74 (0.4x3H, br). ¹³C-NMR (150 MHz, CDCl₃) δ: 173.3, 166.5, 155.38, 155.37, 141.8, 137.7, 129.1, 129.0, 119.8, 111.8, 78.9, 78.8, 52.4, 48.5, 48.1, 47.9, 47.7, 44.1, 44.0, 36.7, 35.2, 34.3, 33.9, 31.9, 31.5, 30.5, 30.2, 29.64, 29.58, 28.2, 27.3, 27.1, 25.5, 25.3, 25.2, 24.7, 20.65, 20.61, 19.1, 19.0, 14.0. IR (KBr): 2926, 1694, 1633, 1393, 1168 cm⁻¹. MS (ESI-TOF) *m/z*: 548/550 (3:1) [M+Na]⁺. HRMS (ESI-TOF) *m/z*: 548.2690 calcd for C₂₇H₄₄N₃O₃S³⁵ClNa; Found: 548.2701.

(4*R*,6*R*)-Biakamide A (1') and B (2')

Combined yield: 85%. HPLC separation provided (4*R*,6*R*)-biakamide A (1') and B (2').

(4*R*,6*R*)-biakamide A (1'): [α]_D²⁶ +5.7 (*c* 2.50, CHCl₃). Mixture of rotamers. ¹H-NMR (600 MHz, CDCl₃) δ: 7.69 (1H, br s), 7.31 (1H, br s), 5.75 (0.4x1H, s), 5.73 (0.6x1H, s), 5.34 (1H, br), 4.85 (2H, s), 4.39 (1H, br), 4.20-4.13 (1H, m), 3.35-3.27 (0.6x2H, m),

3.25-3.15 (0.4x2H, m), 3.00 (3H, br s), 2.92 (0.6x3H, s), 2.89 (0.4x3H, s), 2.55 (1H, br), 2.43 (1H, dd, $J = 16.5, 2.2$ Hz), 2.26 (1H, ddd, $J = 16.5, 9.6, 2.2$ Hz), 2.11 (2H, br), 2.04-1.97 (2H, m), 1.85 (3H, s), 1.65-1.53 (2H, m), 1.40-1.05 (5H, m), 1.19 (3H, d, $J = 6.2$ Hz), 0.94 (3H, br), 0.86 (3H, br). ^{13}C -NMR (150 MHz, CDCl_3) δ : 173.5, 172.5, 172.3, 166.8, 142.1, 141.9, 141.3, 138.1, 129.3, 129.2, 120.0, 112.8, 112.3, 64.2, 64.0, 52.6, 48.9, 48.3, 47.1, 44.2, 41.1, 40.5, 37.0, 35.1, 34.61, 34.57, 33.0, 31.9, 31.6, 30.8, 29.91, 29.88, 27.5, 27.4, 26.0, 25.1, 22.2, 22.1, 20.9, 20.8, 19.3, 14.2. IR (KBr): 3434, 2925, 1627, 1454, 1396 cm^{-1} . MS (ESI-TOF) m/z : 534/536 (3:1) $[\text{M}+\text{Na}]^+$. HRMS (ESI-TOF) m/z : 534.2533 calcd for $\text{C}_{26}\text{H}_{42}\text{N}_3\text{O}_3\text{S}^{35}\text{ClNa}$; Found: 534.2541.

(4*R*,6*R*)-biakamide B (**2'**): $[\alpha]_{\text{D}}^{26} +11.1$ (c 0.81, CHCl_3). Mixture of rotamers. ^1H -NMR (600 MHz, CDCl_3) δ : 7.71 (1H, br s), 7.32 (1H, br s), 5.81 (0.4x1H, s), 5.76 (0.6x1H, s), 5.33 (1H, br), 4.86 (2H, s), 4.45 (1H, br), 4.20-4.14 (1H, m), 3.37 (0.6x2H, t, $J = 7.4$ Hz), 3.29-3.20 (0.4x2H, m), 3.02 (3H, br s), 2.96 (0.6x3H, s), 2.92 (0.4x3H, s), 2.55 (1H, br), 2.46 (1H, dd, $J = 16.1, 7.6$ Hz), 2.28 (1H, dt?, $J = 16.1, 2.2$ Hz), 2.20-2.10 (2H, m), 2.09-1.90 (2H, br), 1.86 (3H, s), 1.69-1.58 (2H, m), 1.35-1.05 (5H, m), 1.21 (3H, d, $J = 6.2$ Hz), 0.95 (3H, br), 0.84 (3H, br). ^{13}C -NMR (150 MHz, CDCl_3) δ : 173.5, 172.5, 172.4, 166.7, 142.1, 142.0, 141.3, 137.9, 129.4, 129.3, 120.1, 113.0, 112.4, 64.2, 64.1, 52.7, 49.2, 48.3, 47.1, 44.44, 44.38, 41.1, 40.4, 37.0, 35.6, 35.5, 35.0, 33.0, 32.2, 32.1, 30.5, 29.9, 29.8, 27.4, 27.3, 26.0, 24.6, 22.2, 22.1, 20.94, 20.89, 19.22, 19.21, 14.2. IR (KBr): 3435, 2925, 1628, 1395, 1258 cm^{-1} . MS (ESI-TOF) m/z : 534/536 (3:1) $[\text{M}+\text{Na}]^+$. HRMS (ESI-TOF) m/z : 534.2533 calcd for $\text{C}_{26}\text{H}_{42}\text{N}_3\text{O}_3\text{S}^{35}\text{ClNa}$; Found: 534.2529.

(4*R*,6*R*)-Biakamide C (3') and D (4')

Combined yield: 76%. HPLC separation provided (4*R*,6*R*)-biakamide C (3') and D (4').

(4*R*,6*R*)-biakamide C (3'): $[\alpha]_D^{27} -11.9$ (*c* 1.32, CHCl₃). Mixture of rotamers. ¹H-NMR (600 MHz, CDCl₃) δ : 7.71 (1H, d, *J* = 1.9 Hz), 7.32 (1H, d, *J* = 1.9 Hz), 5.75 (1H, s), 5.36 (1H, br), 5.14 (0.6x1H, s), 5.13 (0.4x1H, s), 4.86 (2H, s), 3.60 (0.6x3H, s), 3.58 (0.4x3H, s), 3.40-3.30 (0.6x2H, br), 3.32-3.15 (0.4x2H, br), 3.02 (3H, s), 2.99 (0.6x3H, br s), 2.92 (0.4x3H, s), 2.56 (1H, br), 2.18 (3H, s), 2.12 (2H, br), 2.02 (2H, t, *J* = 7.5 Hz), 1.87 (3H, s), 1.67-1.60 (2H, m), 1.40-1.05 (6H, m), 0.95 (3H, d, *J* = 5.5 Hz), 0.86 (3H, d, *J* = 5.2 Hz). ¹³C-NMR (150 MHz, CDCl₃) δ : 173.6, 168.6, 168.5, 168.1, 168.0, 166.8, 142.3, 142.2, 141.6, 138.1, 129.3, 129.2, 120.0, 112.6, 112.1, 91.2, 90.9, 54.8, 52.6, 49.6, 48.4, 47.2, 44.2, 36.9, 36.0, 34.6, 33.4, 32.1, 31.6, 30.8, 29.7, 29.6, 27.6, 27.5, 26.0, 25.5, 20.9, 19.4, 18.7, 14.1. IR (KBr): 2924, 1638, 1450, 1380, 1239 cm⁻¹. MS (ESI-TOF) *m/z*: 546/548 (3:1) [M+Na]⁺. HRMS (ESI-TOF) *m/z*: 546.2533 calcd for C₂₇H₄₂N₃O₃S³⁵ClNa; Found: 546.2511.

(4*R*,6*R*)-biakamide D (4'): $[\alpha]_D^{26} -6.8$ (*c* 0.69, CHCl₃). Mixture of rotamers. ¹H-NMR (600 MHz, CDCl₃) δ : 7.71 (1H, br s), 7.32 (1H, br s), 5.79 (0.5x1H, br s), 5.74 (0.5x1H, br s), 5.33 (1H, b), 5.16 (1H, s), 4.86 (2H, s), 3.60 (0.5x3H, s), 3.59 (0.5x3H, s), 3.41 (0.5x2H, t-like), 3.31 (0.5x2H, t-like), 3.01 (3H+0.5x3H, br s), 2.95 (0.5x3H, br s), 2.55 (1H, br), 2.19 (3H, s), 2.20-2.10 (2H, m), 2.08-1.90 (2H, m), 1.86 (3H, s), 1.69-1.60 (2H, m), 1.38-1.05 (6H, m), 0.95 (3H, d, *J* = 5.3 Hz), 0.83 (3H, br). ¹³C-NMR (150 MHz, CDCl₃) δ : 173.6, 168.4, 168.2, 168.1, 167.8, 166.8, 142.4, 142.2, 141.8, 137.9,

129.5, 129.4, 120.1, 112.8, 112.2, 91.3, 91.0, 54.9, 54.8, 53.0, 50.3, 48.4, 47.3, 44.5, 37.0, 35.9, 35.7, 33.5, 32.33, 32.27, 30.5, 29.9, 29.7, 27.6, 27.5, 26.0, 24.9, 21.0, 19.3, 18.7, 14.3. IR (KBr): 2925, 1644, 1380, 1072 cm^{-1} . MS (ESI-TOF) m/z : 546/548 (3:1) $[\text{M}+\text{Na}]^+$. HRMS (ESI-TOF) m/z : 546.2533 calcd for $\text{C}_{27}\text{H}_{42}\text{N}_3\text{O}_3\text{S}^{35}\text{ClNa}$; Found: 546.2543.

(4*S*,6*R*)-Biakamide A

Using the same procedures as those for the synthesis of the (4*R*,6*S*)-isomer, (4*S*,6*R*)-biakamide A was obtained starting from (2*S*,4*S*)-5-((*tert*-Butyldiphenylsilyl)oxy)-2,4-dimethylpentan-1-ol.⁴¹ (4*S*,6*R*)-biakamide A: $[\alpha]_{\text{D}}^{28} +34.0$ (c 0.70, CHCl_3). Mixture of rotamers. ^1H -NMR (600 MHz, CDCl_3) δ : 7.71 (1H, br s), 7.32 (1H, d, $J = 2.4$ Hz), 5.79 (0.4x1H, s), 5.77 (0.6x1H, s), 5.40 (1H, br), 4.86 (2H, s), 4.39 (0.4x1H, s), 4.38 (0.6x1H, s), 4.20-4.15 (1H, m), 3.35-3.27 (0.6x2H, m), 3.25-3.17 (0.4x2H, m), 3.02 (3H, br s), 2.94 (0.6x3H, s), 2.91 (0.4x3H, s), 2.55 (1H, br), 2.44 (1H, d, $J = 16.8$ Hz), 2.27 (1H, dd, $J = 16.8, 9.6$ Hz), 2.22-2.08 (2H, m), 2.06-2.00 (2H, m), 1.86 (3H, s), 1.70-1.58 (3H, m), 1.40 (2H, br), 1.34-1.10 (3H, m), 1.21 (3H, d, $J = 6.0$ Hz), 0.94 (3H, br), 0.88 (3H, br). ^{13}C -NMR (150 MHz, CDCl_3) δ : 173.6, 172.5, 172.4, 166.9, 142.2, 142.0, 141.4, 138.4, 128.9, 128.8, 120.1, 112.9, 112.4, 64.2, 64.1, 52.6, 49.0, 48.4, 47.2, 44.1, 41.1, 40.5, 37.0, 35.2, 33.86, 33.83, 33.0, 32.1, 31.7, 30.5, 29.78, 29.76, 27.54, 27.49, 26.0, 25.1, 22.2, 22.1, 20.03, 20.00, 19.8, 14.2. IR (KBr): 3409, 2961, 1626, 1454, 1397 cm^{-1} . MS (ESI-TOF) m/z : 534/536 (3:1) $[\text{M}+\text{Na}]^+$. HRMS (ESI-TOF) m/z : 534.2533 calcd for

$C_{26}H_{42}N_3O_3S^{35}ClNa$; Found: 534.2533.

(4*S*,6*S*)-Biakamide A

Using the same procedures as those for the synthesis of the (4*R*,6*S*)-isomer, (4*S*,6*S*)-biakamide A was obtained starting from (2*R*,4*S*)-5-((*tert*-Butyldiphenylsilyl)oxy)-2,4-dimethylpentan-1-ol.⁴³

(4*S*,6*S*)-biakamide A: $[\alpha]_D^{28} +32.5$ (*c* 0.80, $CHCl_3$). Mixture of rotamers. 1H -NMR (600 MHz, $CDCl_3$) δ : 7.72 (1H, br s), 7.32 (1H, br s), 5.77 (0.4x1H, s), 5.76 (0.6x1H, s), 5.37 (1H, br), 4.87 (2H, s), 4.40 (1H, br), 4.20-4.15 (1H, m), 3.35-3.30 (0.6x2H, m), 3.25-3.15 (0.4x2H, m), 3.03 (3H, br s), 2.94 (0.6x3H, s), 2.91 (0.4x3H, s), 2.57 (1H, br), 2.45 (1H, dd, $J = 16.8, 2.4$ Hz), 2.28 (1H, ddd, $J = 16.8, 9.6, 2.4$ Hz), 2.13 (2H, br), 2.06-1.97 (2H, m), 1.88 (3H, s), 1.70-1.58 (2H, m), 1.40-1.08 (5H, m), 1.19 (3H, d, $J = 6.0$ Hz), 0.97 (3H, d, $J = 4.8$ Hz), 0.89 (3H, br). ^{13}C -NMR (150 MHz, $CDCl_3$) δ : 173.6, 172.6, 172.4, 166.9, 142.2, 141.9, 141.4, 138.1, 129.4, 129.3, 120.1, 112.9, 112.4, 64.2, 64.1, 52.6, 49.0, 48.3, 47.2, 44.3, 41.1, 40.5, 37.0, 35.2, 34.7, 34.6, 33.1, 32.0, 31.7, 30.8, 29.99, 29.96, 27.6, 27.5, 26.0, 25.2, 22.3, 22.2, 21.0, 20.9, 19.4, 14.3. IR (KBr): 3435, 2925, 1627, 1454, 1396 cm^{-1} . MS (ESI-TOF) m/z : 534/536 (3:1) $[M+Na]^+$.

HRMS (ESI-TOF) m/z : 534.2533 calcd for $C_{26}H_{42}N_3O_3S^{35}ClNa$; Found: 534.2548.

Biological evaluation of biakamides A-D

Materials

Dulbecco's Modified Eagle's medium (DMEM), WST-8 colorimetric reagent, and

KCN were purchased from Nacalai Tesque, Inc. (Kyoto, Japan). Fetal bovine serum (FBS) and Dialyzed FBS were purchased from Equitech-Bio Inc. (Kerrville, TX, USA) and Thermo Fisher Scientific Inc. (Waltham, MA, USA), respectively. Anti-Akt, Anti-phosphorylated Akt, anti-GRP78, and anti- β -tubulin antibodies were obtained from Cell Signaling Technology, Inc. (Danvers, MA, USA). Horseradish peroxidase (HRP)-linked anti-rabbit IgG antibody (GE Healthcare Life Sciences, Buckinghamshire, UK) was used as secondary antibody. Mito Check Complex Activity Assay Kit (Cayman Chemical, Ann Arbor, MI, USA) was used to evaluate the effect of biakamide C (3) on the mitochondrial complex I–V. Rotenone, thenoyltrifluoroacetone (TTFA), antimycin A, and oligomycin mixture were obtained from Tokyo Chemical Industry Co., LTD. (Tokyo, Japan), Wako Pure Chemical Industries, Ltd. (Osaka, Japan), LKT Laboratories, Inc. (St. Paul, MN, USA), and Cayman Chemical (Ann Arbor, MI, USA), respectively. Other chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) or Kishida Chemical Co., Ltd. (Osaka, Japan).

Cell cultures

Human pancreatic cancer cell line PANC-1 was cultured in DMEM supplemented with heat-inactivated 10% fetal bovine serum (FBS) and kanamycin (50 μ g/mL) in a humidified atmosphere of 5% CO₂ at 37 °C. In the case of the conditions of nutrient starvation, PANC-1 cells was cultured in the Glucose Deficient Medium [Basal Medium (25 mM HEPES buffer (pH 7.4) supplemented with 6.4 g/L NaCl, 700 mg/L NaHCO₃, 400 mg/L KCl, 265 mg/L CaCl₂•2H₂O, 200 mg/L MgSO₄•7H₂O, 125 mg/L NaH₂PO₄,

0.1 mg/L $\text{Fe}(\text{NO}_3)_3 \cdot 9\text{H}_2\text{O}$, 15 mg/L Phenol red, 10 mL/L MEM vitamin solution ($\times 100$) (GIBCO, Carlsbad, CA), 200 mmol/L L-glutamine solution (GIBCO, Carlsbad, CA), 25 mg/L kanamycin) containing 10% dialyzed FBS]. The General Glucose Medium [Basal Medium supplemented with 10% FBS and 2.0 g/L glucose (final 25 mM)] was also used for bioassay as the general culture conditions to compare the activity of the sample under the conditions of nutrient starvation.

Assay for growth inhibitory activity under glucose-deprived condition

The PANC-1 cells in the culture medium were plated into each well of 96-well plates (1×10^4 cells/well/100 μL) for 12 h in a humidified atmosphere of 5% CO_2 at 37 $^\circ\text{C}$. After removal of the medium, the cells in each well were rinsed with PBS twice. Then, the plates were incubated in either General Glucose Medium or Glucose Deficient Medium inducing adaptation toward austerity. After 12 h incubation, testing compounds were added as an EtOH solution (1 μL), and then the plates were incubated for an additional 12 h. The anti-proliferative activities of the testing compounds under the respective conditions were evaluated by colorimetric assay using WST-8 reagent, and the growth inhibition rate was calculated as percentage of parallel negative controls.

Western blotting analysis

PANC-1 cells (3.0×10^5 cells/2 mL in 6 well plastic plate) were pre-incubated in the DMEM supplement with 10 % FBS for 24 h. The medium was then replaced with either General Glucose or Glucose Deficient Medium. After 12 h incubation, biakamide C (**3**,

0.5 μ M) or antimycin A (3.0 nM) as a positive control was added, and the cells were incubated for additional 12 h in a humidified atmosphere of 5 % CO₂ at 37 °C. Then, the cells were rinsed with ice-cold PBS and lysed in the lysis buffer (50 mM Tris-HCl (pH 8.0) containing 137 mM NaCl, 5 mM EDTA-2Na, 0.1% NP-40, 1% glycerol, 1% protease inhibitor cocktail, and 1% phosphatase inhibitor cocktail). The cell lysate was subjected to SDS-PAGE and transferred onto PVDF membranes (GE Healthcare Life Sciences Buckinghamshire, UK). The membranes were then incubated with appropriate primary antibodies and HRP-conjugated secondary antibodies, and the immunopositive bands were visualized using an ECL kit (GE Healthcare Life Sciences). The luminescent signals were analyzed using an ImageQuant LAS4010 Scanner (GE Healthcare Life Sciences).

Acknowledgments

The authors are grateful to Dr. Nicole J. de Voogd of the National Museum of Natural History, the Netherlands for identification of the sponge; Mrs. Toshie Minematsu of the Joint Research Center, Kindai University, Japan for NMR measurements. The authors are also grateful to MEXT/JSPS KAKENHI (grant nos. JP23102005, JP26242074, and JP15K07996) for financial support. This study was also supported by the Platform Project for Supporting Drug Discovery and Life Science Research (Platform for Drug

Discovery, Informatics, and Structural Life Science) from MEXT and the Japan Agency for Medical Research and Development (AMED).

Supporting Information Available

^1H and ^{13}C NMR signal assignments of biakamides B (**2**), C (**3**), and D (**4**), 1D and 2D NMR spectra of the biakamides A–D (**1–4**) and synthetic compounds **1–20**, and the result of western blot analysis. This material is available free of charge via the Internet at <http://pubs.acs.org>.

References

1. Vaupel, P.; Kallinowski, F.; Okunieff, P. *Cancer Res.* **1989**, *49*, 6449–6465.
2. Rohwer, N.; Cramer, T. *Drug Resist. Updates* **2011**, *14*, 191–201.
3. Molinski, T. F.; Dalisay, D. S.; Lievens, S. L.; Saludes, J. P. *Nat. Rev. Drug Discov.* **2009**, *8*, 69–85.
4. Harvey, A. L.; Edrada-Ebel, R.; Quinn, R. J. *Nat. Rev. Drug Discov.* **2015**, *14*, 111–129.

- 1
2
3
4
5
6 5. Arai, M.; Kawachi, T.; Setiawan, A.; Kobayashi, M. *ChemMedChem* **2010**, *5*, 1919–
7
8 1926.
9
10
11
12 6. Arai, M.; Kawachi, T.; Sato, H.; Setiawan, A.; Kobayashi, M. *Bioorg. Med. Chem.*
13
14 *Lett.* **2014**, *24*, 3155–3157.
15
16
17
18 7. Kotoku, N.; Fujioka, S.; Nakata, C.; Yamada, M.; Sumii, Y.; Kawachi, T.; Arai, M.;
19
20 Kobayashi, M. *Tetrahedron* **2011**, *67*, 6673–6678.
21
22
23
24 8. Kotoku, N.; Nakata, C.; Kawachi, T.; Sato, T.; Guo, X.; Ito, A.; Sumii, Y.; Arai, M.;
25
26 Kobayashi, M. *Bioorg. Med. Chem.* **2014**, *22*, 2102–2112.
27
28
29
30 9. Arai, M.; Kawachi, T.; Kotoku, N.; Nakata, C.; Kamada, H.; Tsunoda, S.; Tsutsumi,
31
32 Y.; Endo, H.; Inoue, M.; Sato, H.; Kobayashi, M. *ChemBioChem* **2016**, *17*, 181–189.
33
34
35
36 10. Sumii, Y.; Kotoku, N.; Fukuda, A.; Kawachi, T.; Sumii, Y.; Arai, M.; Kobayashi, M.
37
38 *Bioorg. Med. Chem.* **2015**, *23*, 966–975.
39
40
41
42 11. Sumii, Y.; Kotoku, N.; Fukuda, A.; Kawachi, T.; Arai, M.; Kobayashi, M. *Marine*
43
44 *Drugs* **2015**, *13*, 7419–7432.
45
46
47
48
49 12. Izuishi, K.; Kato, K.; Ogura, T.; Kinoshita, T.; Esumi, H. *Cancer Res.* **2000**, *60*,
50
51 6201–6207.
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 13. Onozuka, H.; Tsuchihara, K.; Esumi, H. *Cancer Sci.* **2011**, *102*, 975–982.
7
8
9
10 14. Lu, J.; Kunimoto, S.; Yamazaki, Y.; Kaminishi, M.; Esumi, H. *Cancer Sci.* **2004**, *95*,
11
12 547–552.
13
14
15
16 15. Awale, S.; Ju, J.; Kalauni, S. K.; Kurashima, Y.; Tezuka, Y.; Kadota, S.; Esumi, H.
17
18
19 *Cancer Res.* **2006**, *66*, 1751–1757.
20
21
22 16. Magolan, J.; Coster, M. J. *Curr. Drug Deliv.* **2010**, *7*, 355–369.
23
24
25
26 17. Strimpakos, S. A.; Saif, M. W. *J. Pancreas* **2013**, *14*, 354–358.
27
28
29 18. Arai, M.; Kamiya, K.; Shin, D.; Matsumoto, H.; Hisa, T.; Setiawan, A.; Kotoku, N.;
30
31 Kobayashi, M. *Chem. Pharm. Bull.* **2016**, *64*, 766–771.
32
33
34
35 19. Arai, M.; Shin, D.; Kamiya, K.; Ishida, R.; Setiawan, A.; Kotoku, N.; Kobayashi, M.
36
37
38
39 *J. Nat Med.* **2017**, *71*, 44–49.
40
41
42 20. Orjala, J.; Gerwick, W. H. *J. Nat. Prod.* **1996**, *59*, 427–430.
43
44
45 21. Unson, M. D.; Rose, C. B.; Faulkner, D. J.; Brinen, L. S.; Steiner, J. R.; Clardy, J. J.
46
47
48 *Org. Chem.* **1993**, *58*, 6336–6343.
49
50
51 22. Shaala, L. A.; Youssef, D. T. A.; McPhail, K. L.; Elbandy, M. *Phytochem. Lett.* **2013**,
52
53
54 6, 183–188.
55
56
57
58
59
60

23. Edwards, D. J.; Marquez, B. L.; Nogle, L. M.; McPhail, K.; Goeger, D. E.; Ann Roberts, M.; Gerwick, W. H. *Chem. Biol.* **2004**, *11*, 817–833.
24. Balunas, M. J.; Linington, R. G.; Tidgewell, K.; Fenner, A. M.; Urena, L.-D.; Togna, G. D.; Kyle, D. E.; Gerwick, W. H. *J. Nat. Prod.* **2010**, *73*, 60–66.
25. Ohtani, I.; Kusumi, T.; Kashman, Y.; Kakisawa, H. *J. Am. Chem. Soc.* **1991**, *113*, 4092–4096.
26. Jansen, R.; Kunze, B.; Reichenbach, H.; Hofle, G. *Eur. J. Org. Chem.* **2002**, 917–921.
27. Schmidt, Y.; Lehr, K.; Colas, L.; Breit, B. *Chem. Eur. J.* **2012**, *18*, 7071–7081.
28. Yoshimura, A.; Kishimoto, S.; Nishimura, S.; Otsuka, S.; Sakai, Y.; Hattori, A.; Kakeya, H. *J. Org. Chem.* **2014**, *79*, 6858–6867.
29. Fujita, K.; Mori, K. *Eur. J. Org. Chem.* **2001**, 493–502.
30. Seebach, D.; Corey, E. J. *J. Org. Chem.* **1975**, *40*, 231–237.
31. Wilke, B. I.; Dornan, M. H.; Yeung, J.; Boddy, C. N.; Pinto, A. *Tetrahedron Lett.* **2014**, *55*, 2600–2602.
32. Vatele, J.-M. *Tetrahedron Lett.* **2006**, *47*, 715–718.

33. Samajdar, S.; Basu, M. K.; Becker, F. F.; Banik, B. K. *Tetrahedron Lett.* **2001**, *42*, 4425–4427.
34. Gunosewoyo, H.; Midzak, A.; Gaisina, I. N.; Sabath, E. V.; Fedolak, A.; Hanania, T.; Brunner, D.; Papadopoulos, V.; Kozikowski, A. P. *J. Med. Chem.* **2013**, *56*, 5115–5129.
35. Laganis, E. D.; Chenard, B. L. *Tetrahedron Lett.* **1984**, *25*, 5831–5834.
36. Han, J.; Lian, J.; Tian, X.; Zhou, S.; Zhen, X.; Liu, S. *Eur. J. Org. Chem.* **2014**, 7232–7238.
37. Krebs, O.; Taylor, R. J. K. *Org. Lett.* **2005**, *7*, 1063–1066.
38. Lin, G.-Q.; Xu, W.-C. *Bioorg. Med. Chem.* **1996**, *4*, 375–380.
39. Momose, I.; Ohba, S.; Tatsuda, D.; Kawada, M.; Masuda, T.; Tsujiuchi, G.; Yamori, T.; Esumi, H.; Ikeda, D. *Biochem. Biophys. Res. Commun.* **2010**, *392*, 460–466.
40. Cha, M.-R.; Yoon, M.-Y.; Son, E.-S.; Park, H.-R. *Biosci. Biotechnol. Biochem.* **2009**, *73*, 2167–2171.
41. Tae, H. S.; Hines, J.; Schneekloth, A. R.; Crews, C. M. *Bioorg. Med. Chem.* **2011**, *19*, 1708–1713.

42. Chen, J.; Forsyth, C. J. *Angew. Chem. Int. Ed.* **2004**, *43*, 2148-2152.

43. Nagamitsu, T.; Takano, D.; Fukuda, T.; Ootoguro, K.; Kuwajima, I.; Harigaya, Y.;
Omura, S. *Org. Lett.* **2004**, *6*, 1865-1867.